基于靶标的HIV-1非核苷类逆转录酶抑制剂的设计、合成及活性研究
|
摘要
人免疫缺陷病毒1型(HIV-1)是艾滋病的主要病原体。自从1981年发现以来,目前已经成为危害人类生命健康的重大传染性疾病。虽然高效抗逆转录疗法(Highly Active Antiretro viral Therapy, HAART)的实施是抗艾滋病治疗的一项重大突破,但是耐药性的出现及长期服药的毒性问题极大地限制了该疗法的应用,因此新型抗艾滋病药物的研发依然刻不容缓。
HIV-1非核苷类逆转录酶抑制剂(NNRTIs)是HAART疗法的重要组成部分。NNRTIs具有结构多样性,作用于HIV-1逆转录酶(Reverse Transcriptase, RT)的疏水性口袋。该类药物具有高效低毒、特异性强的优点,然而易产生耐药性的缺陷使该类药物迅速丧失临床效价。因此新型、高效、低毒、广谱抗耐药性的NNRTIs的研发是目前抗HIV药物研究的热点之一。
由于NNRTIs结合口袋(Non-nucleoside Inhibitor-Binding Pocket, NNIBP)是在NNRTIs的存在下诱导产生的,因此完全基于HIV-1RT的三维结构进行全新抑制剂设计还存在较大困难。故选择研发前景较大的化合物为先导,在对其构效关系及结合模式分析的基础上,综合运用结构生物学信息、计算化学技术及传统药物化学策略进行先导化合物的优化,是当前发现新一代NNRTIs药物的有效途径。本论文对三类HIV-1RT非核苷类逆转录酶抑制剂进行了研究。
一、硝基吡啶类DAPYs非核苷类逆转录酶抑制剂的研究
二芳基嘧啶类衍生物(DAPYs)是一类非核苷类HIV-1逆转录酶抑制剂,因其高效低毒、抗耐药性的特点,近年来成为抗HIV药物研发的热点领域。2008年FDA批准上市的新一代NNRTIs Etravirine(TMC125)及2011年批准的Rilpivirine(TMC278)都属于DAPY类化合物。本论文基于DAPY类逆转录酶抑制剂的构效关系和DAPYs/HIV-1RT复合物晶体结构的分析,应用生物电子等排原理,将原本的嘧啶环替换为硝基吡啶环,设计了一系列硝基吡啶类DAPY系列衍生物(7a-7r),并对其进行了定向合成。该系列共合成了18个化合物,所有合成的化合物的结构均经波谱分析验证。
对所合成的化合物应用MTT法进行了体外抗野生型HIV-1(ⅢB).HIV-2(ROD)及HIV-1突变毒株的细胞活性测试。其中,化合物7b显示出最佳的抗病毒活性(EC50=0.056μM,SI=1251).此外,化合物7k(EC50=0.034μM,SI=691),化合物7c(EC50=0.11μM,SI:339)和7h(EC50=0.17μM,SI=97)活性均比对照药物NVP和DLV高。选取活性较好的化合物7b、7c和7k进行了HIV-1逆转录酶的抑制活性测定,抑制活性分别为6.9μM.8.5μM和10.4μM,显示出了该类化合物对HIV-1RT选择性的抑制作用。
利用DOCk分子对接方法,将活性最好的化合物7b和7k与野生型HIV-1RT和突变型的HIV-1RT分别进行分子模拟,并对该系列化合物与HIV-1RT的相互作用及构效关系进行了初步分析,为未来设计新型的高效低毒的DAPYs非核苷类逆转录酶抑制剂提供了有益的信息。
二、噻唑烷酮类非核苷类逆转录酶抑制剂的研究
噻唑烷酮类化合物是一类结构新颖的NNRTIs,经结构的修饰和改造,发现了很多具有很高抗HIV-1活性的噻唑烷酮类化合物,具有非常广阔的研发前景。硫代羧酰苯胺类衍生物(thiocarboxanilide)UC-781是一个非常有效的HIV-1RT抑制剂候选药物(EC50=0.002μ.M,SI=50000).UC-781可以降低病毒颗粒的感染力,被认为是预防HIV-1传播的很有希望的化合物。此外,该化合物具有良好的抗耐药谱,对多种突变毒株RT的抑制效果与对野生型HIV-1RT的接近,且可以在高剂量水平抑制NNRTIs耐药病毒株而无任何细胞毒性。
以噻唑烷酮类NNRTIs和UC-781为先导物,借鉴两类NNRTIs的结构特征及与RT的结合模式,结合两类化合物的相似点,运用分子杂合的药物设计原理,合理地引入活性取代基,保留了先导化合物UC-781的异戊烯基基团,设计了一系列与靶点紧密结合的新型噻唑烷酮类系列化合物。并对目标化合物进行了定向合成,所有合成的化合物的结构均经波谱验证。应用MTT法对所合成的化合物进行了体外抗野生型HIV-1(ⅢB)、HIV-2(ROD)细胞活性测定。试验结果表明,部分噻唑烷酮类化合物表现出了一定的活性,但细胞毒性略高。将其中活性最好的化合物与HIV-1RT进行分析对接,对该类化合物的构效关系进行了初步分析,初步阐明了该类化合物与HIV-1RT的结合位点与构象,解释活性略低的可能原因,为进一步结构的优化提供新的思路。
三、DABOs类非核苷类逆转录酶抑制剂
二氢烷氧苄基嘧啶酮(Dihydro-alkylthio-benzyl-oxopyrimidines, DABOs)衍生物为其中较为典型的一类NNRTIs,由于其分子构象具有柔性和结合位点中具有适配性的特征,可有效地抑制野生型和耐药型病毒株的复制,成为目前抗HIV药物研究的重要方向。
本论文基于DABO类抑制剂的构效关系,结合计算机对接模型,依据分子杂化的药物设计原理,以取代哌啶环来延长侧链的S-DABOs衍生物,通过变化哌啶环N原子上取代基、母环的5位、6位取代基来考察化合物各位点对活性的影响,并以未连有哌啶环的另一系列化合物作为对照共合成了两个系列化合物。为了从理论上验证设计思想的合理性,对设计的化合物进行了对接分析,分析结果表明目标分子的结构修饰具有理论上的合理性。最后根据虚拟筛选的结果,从高到低打分,确定并合成了36个目标化合物,并选取打分较高的化合物进行了HIV-1RT的活性测定。活性结果显示,化合物8a3-2、8a2-1和8b3-2对HIV-1RT的抑制活性分别为1.58μM、14.61μM和13.71μM,显示出了一定的HIV-1RT抑制活性,其中在虚拟筛选中打分最高的化合物8a3-2(IC50=1.58μM)的活性高于对照药奈韦拉平(IC5o=3.93μM),并与先导化合物TMC125(IC5o=1.05μM)类似,表现了较高的HIV-1RT抑制活性。
总之,本论文以高效抗耐药的DAPYs、噻唑烷酮类和DABOs三类NNRTIs先导化合物为模板,在前人研究的基础上,结合构效关系结论及药效团特征,分别根据药物设计中的生物电子等排原理和分子杂化原理,对先导化合物进行了结构多样的骨架变换,并应用药物设计软件进行虚拟筛选。总共设计合成了四个系列结构全新的化合物。对目标化合物进行了抗HIV活性筛选,发现其中部分化合物的抗HIV-1(IIIB)活性达到或超过上市药物奈韦拉平与地拉韦定,具有进一步研究与开发价值。此外,还对目标化合物进行了计算机分子对接研究,根据其与HIV-1RT的结合模式对化合物的构效关系进行了初步分析,为进一步的研究提供了有利的信息。
The human immunodeficiency virus type1(HIV-1) is the main cause of the acquired immunodeficiency syndrome (AIDS), which was first identified in the Western world in1981. Since then, AIDS has developed into a worldwide pandemic of disastrous proportions. Considerable progress has been made in treating HIV-infected patients using highly active antiretroviral therapy (HAART) involving multidrug combinations. However, the increasing incidence of drug resistant viruses along with the drug toxicity among treated people calls for continuous efforts of developing anti-HIV-1drugs.
HIV-1reverse transcriptase (RT) is one of the main targets for the action of anti-AIDS drugs. Drugs targeted at HIV RT can be divided into two categories:(ⅰ) nucleoside and nucleotide analogue RT inhibitors (NRTIs/NtRTIs), which, following activation to their triphosphate forms, compete with the RT substrate and also act as terminators of DNA synthesis after incorporation into the primer strand; and (ⅱ) nonnucleoside RT inhibitors (NNRTIs), including the approved drugs nevirapine, delavirdine, efavirenz and etravirine, which, although having wide structural variation, all bind at a similar site distal to the active site within RT. NNRTIs currently in clinical use have a low genetic barrier to resistance and therefore, the need for novel NNRTIs active against drug-resistant mutants selected by current therapies is of paramount importance.
In recent year, in spite of the rapid growth of HFV-1RT3D-structural information, the difficulty in structure-based de novo design of NNRTIs scaffolds and docking based virtual screening approach lies in the following two aspects:i) The flexibility of NNIBP, formed by conformational changes in the RT on binding of the NNRTI ligand; ii) The NNRTI resistance mutations located in and around the NNIBP. Therefore, structure-based and ligand-based combined drug design methodology was carried out to facilitate both drug lead generation and lead optimization. And considerable cases illustrated the benefits for NNRTIs design of closely coupled traditional medicinal chemistry, structural biology, computational chemistry methodology, and many others.
As a continuation of our efforts to discover and develop back-up analogs of DAPYs, novel substituted nitropyridine derivatives were designed via a structure-based core refining approach, synthesized and evaluated for their in vitro HIV-1activity in MT-4cells. Preliminary biological evaluation indicated that most of the compounds exhibited marked inhibitory activity against wild-type HIV-1IIIB. Most notably, the compound7b was identified as the most promising candidate in inhibiting HIV-1replication with an EC50value of0.056μM and a selective index (SI) of1251,7k (EC50=0.034μM, SI=691), compound7c (EC50=0.11μM, SI=339) and compound7h (EC50=0.17μM, SI=97) were more active than reference drugs NVP(EC50=0.23μM) and DLV(EC5o=0.51μM) against wt HIV-1(ⅢB). Some antivirally active compounds also showed moderate inhibitory activity against RT. Preliminary structure-activity relationships (SARs) and molecular modeling of these new analogs provide valuable avenues for future molecular optimization.
Substituted2,3-diaryl-1,3-thiazolidin-4-one derivatives represented a new class of specific HIV-1NNRTIs. Thiocarboxanilide derivatives UC781,(N-[4-chloro-3-(3-methyl-2-butenyloxy)pheny1]-2-methyl-3-furancarbothiomide), is a extremely potent inhibitor of human immunodeficiency virus type1(HIV-1) reverse transcriptase (RT) with a favorable resistance spectrum. The EC50and SI of UC781inhibited of HIV-1replication in cell culture were0.002μM and50000, respectively. UC781targeted HIV-1RT and had extremely low and almost similar EC50values against wild-type HIV-1and a series of mutant viruses in their RT and restored the anti viral activity of AZT to AZT resistant HIV-1strains. Based on the general crystal structure of the HIV-1RT complexed with NNRTIs, which is like a "butterfly"type, and furthermore,2,3-diaryl-1,3-thiazolidin-4-one and UC-781are served as templates, and according to the general principle of bioisosteric replacement in medicinal chemistry, we designed and synthesized a series of novel2,3-diaryl-1,3-thiazolidin-4-one derivatives in which the2,6-dihalophenyl ring at C-2was retained as an essential moiety, whereas the pyridine ring was replaced by a suitably substituted benzene ring. All the newly compounds are screened for anti-HIV activity in vitro. The results showed that some compunds exhibited inhibition against HIV-1replication, Structure-activity relationship analysis revealed that the different substitute aromatic ring played an important role in affecting the anti-HIV activities. Structure-activity relation was discussed and some useful information was obtained in the design and development of new HIV-1NNRTIs.
Among the most representative classes of NNRTIs, DABOs (dihydro-alkylthio-benzyl-oxopyrimidines) occupy a relevant position. Owing to their structures, DABOs can adapt to changes in the binding pocket due to mutations. So DABOs can inhibit the mutation of the target and also inhibit the emergence of drug resistance. Based on computer aided drug design (CADD), we have designed and synthesized novel DABOs derivatives:piperidine-linked S-DABO analogues. We have also used molecular docking to study the relationship between compounds and HIV-1RT, which provide clear guideline and actual activity predicitions for novel HIV-1RT inhibitors. The selected target molecules based on docking results of virtual screening were synthesized. The preliminary activity and cytotoxicity screening of the newly designed and synthesized target compounds S-DABOs for inhibition of HIV-1(strain IIIB), HIV-2(strain ROD) and HIV-1mutant virus strains are in progress.
In summary, taking the DAPYs,2,3-Diaryl-1,3-thiazolidin-4-one derivatives and DABOs NNRTIs as leads, four series of novel NNRTIs were designed and synthesized in this dissertation according to bioisosterism principle. The new, simple, and convenient synthetic approaches to the title compounds were developed, or improved and optimized. Lastly, through biological evaluation, we find many high potent antiviral agents, which are worth further investigation and development. We hope that the knowledge and insight on the NNRTIs research learnt from the work will help a lot on the battle against the virus and benefit human health and life.
HIV-1非核苷类逆转录酶抑制剂(NNRTIs)是HAART疗法的重要组成部分。NNRTIs具有结构多样性,作用于HIV-1逆转录酶(Reverse Transcriptase, RT)的疏水性口袋。该类药物具有高效低毒、特异性强的优点,然而易产生耐药性的缺陷使该类药物迅速丧失临床效价。因此新型、高效、低毒、广谱抗耐药性的NNRTIs的研发是目前抗HIV药物研究的热点之一。
由于NNRTIs结合口袋(Non-nucleoside Inhibitor-Binding Pocket, NNIBP)是在NNRTIs的存在下诱导产生的,因此完全基于HIV-1RT的三维结构进行全新抑制剂设计还存在较大困难。故选择研发前景较大的化合物为先导,在对其构效关系及结合模式分析的基础上,综合运用结构生物学信息、计算化学技术及传统药物化学策略进行先导化合物的优化,是当前发现新一代NNRTIs药物的有效途径。本论文对三类HIV-1RT非核苷类逆转录酶抑制剂进行了研究。
一、硝基吡啶类DAPYs非核苷类逆转录酶抑制剂的研究
二芳基嘧啶类衍生物(DAPYs)是一类非核苷类HIV-1逆转录酶抑制剂,因其高效低毒、抗耐药性的特点,近年来成为抗HIV药物研发的热点领域。2008年FDA批准上市的新一代NNRTIs Etravirine(TMC125)及2011年批准的Rilpivirine(TMC278)都属于DAPY类化合物。本论文基于DAPY类逆转录酶抑制剂的构效关系和DAPYs/HIV-1RT复合物晶体结构的分析,应用生物电子等排原理,将原本的嘧啶环替换为硝基吡啶环,设计了一系列硝基吡啶类DAPY系列衍生物(7a-7r),并对其进行了定向合成。该系列共合成了18个化合物,所有合成的化合物的结构均经波谱分析验证。
对所合成的化合物应用MTT法进行了体外抗野生型HIV-1(ⅢB).HIV-2(ROD)及HIV-1突变毒株的细胞活性测试。其中,化合物7b显示出最佳的抗病毒活性(EC50=0.056μM,SI=1251).此外,化合物7k(EC50=0.034μM,SI=691),化合物7c(EC50=0.11μM,SI:339)和7h(EC50=0.17μM,SI=97)活性均比对照药物NVP和DLV高。选取活性较好的化合物7b、7c和7k进行了HIV-1逆转录酶的抑制活性测定,抑制活性分别为6.9μM.8.5μM和10.4μM,显示出了该类化合物对HIV-1RT选择性的抑制作用。
利用DOCk分子对接方法,将活性最好的化合物7b和7k与野生型HIV-1RT和突变型的HIV-1RT分别进行分子模拟,并对该系列化合物与HIV-1RT的相互作用及构效关系进行了初步分析,为未来设计新型的高效低毒的DAPYs非核苷类逆转录酶抑制剂提供了有益的信息。
二、噻唑烷酮类非核苷类逆转录酶抑制剂的研究
噻唑烷酮类化合物是一类结构新颖的NNRTIs,经结构的修饰和改造,发现了很多具有很高抗HIV-1活性的噻唑烷酮类化合物,具有非常广阔的研发前景。硫代羧酰苯胺类衍生物(thiocarboxanilide)UC-781是一个非常有效的HIV-1RT抑制剂候选药物(EC50=0.002μ.M,SI=50000).UC-781可以降低病毒颗粒的感染力,被认为是预防HIV-1传播的很有希望的化合物。此外,该化合物具有良好的抗耐药谱,对多种突变毒株RT的抑制效果与对野生型HIV-1RT的接近,且可以在高剂量水平抑制NNRTIs耐药病毒株而无任何细胞毒性。
以噻唑烷酮类NNRTIs和UC-781为先导物,借鉴两类NNRTIs的结构特征及与RT的结合模式,结合两类化合物的相似点,运用分子杂合的药物设计原理,合理地引入活性取代基,保留了先导化合物UC-781的异戊烯基基团,设计了一系列与靶点紧密结合的新型噻唑烷酮类系列化合物。并对目标化合物进行了定向合成,所有合成的化合物的结构均经波谱验证。应用MTT法对所合成的化合物进行了体外抗野生型HIV-1(ⅢB)、HIV-2(ROD)细胞活性测定。试验结果表明,部分噻唑烷酮类化合物表现出了一定的活性,但细胞毒性略高。将其中活性最好的化合物与HIV-1RT进行分析对接,对该类化合物的构效关系进行了初步分析,初步阐明了该类化合物与HIV-1RT的结合位点与构象,解释活性略低的可能原因,为进一步结构的优化提供新的思路。
三、DABOs类非核苷类逆转录酶抑制剂
二氢烷氧苄基嘧啶酮(Dihydro-alkylthio-benzyl-oxopyrimidines, DABOs)衍生物为其中较为典型的一类NNRTIs,由于其分子构象具有柔性和结合位点中具有适配性的特征,可有效地抑制野生型和耐药型病毒株的复制,成为目前抗HIV药物研究的重要方向。
本论文基于DABO类抑制剂的构效关系,结合计算机对接模型,依据分子杂化的药物设计原理,以取代哌啶环来延长侧链的S-DABOs衍生物,通过变化哌啶环N原子上取代基、母环的5位、6位取代基来考察化合物各位点对活性的影响,并以未连有哌啶环的另一系列化合物作为对照共合成了两个系列化合物。为了从理论上验证设计思想的合理性,对设计的化合物进行了对接分析,分析结果表明目标分子的结构修饰具有理论上的合理性。最后根据虚拟筛选的结果,从高到低打分,确定并合成了36个目标化合物,并选取打分较高的化合物进行了HIV-1RT的活性测定。活性结果显示,化合物8a3-2、8a2-1和8b3-2对HIV-1RT的抑制活性分别为1.58μM、14.61μM和13.71μM,显示出了一定的HIV-1RT抑制活性,其中在虚拟筛选中打分最高的化合物8a3-2(IC50=1.58μM)的活性高于对照药奈韦拉平(IC5o=3.93μM),并与先导化合物TMC125(IC5o=1.05μM)类似,表现了较高的HIV-1RT抑制活性。
总之,本论文以高效抗耐药的DAPYs、噻唑烷酮类和DABOs三类NNRTIs先导化合物为模板,在前人研究的基础上,结合构效关系结论及药效团特征,分别根据药物设计中的生物电子等排原理和分子杂化原理,对先导化合物进行了结构多样的骨架变换,并应用药物设计软件进行虚拟筛选。总共设计合成了四个系列结构全新的化合物。对目标化合物进行了抗HIV活性筛选,发现其中部分化合物的抗HIV-1(IIIB)活性达到或超过上市药物奈韦拉平与地拉韦定,具有进一步研究与开发价值。此外,还对目标化合物进行了计算机分子对接研究,根据其与HIV-1RT的结合模式对化合物的构效关系进行了初步分析,为进一步的研究提供了有利的信息。
The human immunodeficiency virus type1(HIV-1) is the main cause of the acquired immunodeficiency syndrome (AIDS), which was first identified in the Western world in1981. Since then, AIDS has developed into a worldwide pandemic of disastrous proportions. Considerable progress has been made in treating HIV-infected patients using highly active antiretroviral therapy (HAART) involving multidrug combinations. However, the increasing incidence of drug resistant viruses along with the drug toxicity among treated people calls for continuous efforts of developing anti-HIV-1drugs.
HIV-1reverse transcriptase (RT) is one of the main targets for the action of anti-AIDS drugs. Drugs targeted at HIV RT can be divided into two categories:(ⅰ) nucleoside and nucleotide analogue RT inhibitors (NRTIs/NtRTIs), which, following activation to their triphosphate forms, compete with the RT substrate and also act as terminators of DNA synthesis after incorporation into the primer strand; and (ⅱ) nonnucleoside RT inhibitors (NNRTIs), including the approved drugs nevirapine, delavirdine, efavirenz and etravirine, which, although having wide structural variation, all bind at a similar site distal to the active site within RT. NNRTIs currently in clinical use have a low genetic barrier to resistance and therefore, the need for novel NNRTIs active against drug-resistant mutants selected by current therapies is of paramount importance.
In recent year, in spite of the rapid growth of HFV-1RT3D-structural information, the difficulty in structure-based de novo design of NNRTIs scaffolds and docking based virtual screening approach lies in the following two aspects:i) The flexibility of NNIBP, formed by conformational changes in the RT on binding of the NNRTI ligand; ii) The NNRTI resistance mutations located in and around the NNIBP. Therefore, structure-based and ligand-based combined drug design methodology was carried out to facilitate both drug lead generation and lead optimization. And considerable cases illustrated the benefits for NNRTIs design of closely coupled traditional medicinal chemistry, structural biology, computational chemistry methodology, and many others.
As a continuation of our efforts to discover and develop back-up analogs of DAPYs, novel substituted nitropyridine derivatives were designed via a structure-based core refining approach, synthesized and evaluated for their in vitro HIV-1activity in MT-4cells. Preliminary biological evaluation indicated that most of the compounds exhibited marked inhibitory activity against wild-type HIV-1IIIB. Most notably, the compound7b was identified as the most promising candidate in inhibiting HIV-1replication with an EC50value of0.056μM and a selective index (SI) of1251,7k (EC50=0.034μM, SI=691), compound7c (EC50=0.11μM, SI=339) and compound7h (EC50=0.17μM, SI=97) were more active than reference drugs NVP(EC50=0.23μM) and DLV(EC5o=0.51μM) against wt HIV-1(ⅢB). Some antivirally active compounds also showed moderate inhibitory activity against RT. Preliminary structure-activity relationships (SARs) and molecular modeling of these new analogs provide valuable avenues for future molecular optimization.
Substituted2,3-diaryl-1,3-thiazolidin-4-one derivatives represented a new class of specific HIV-1NNRTIs. Thiocarboxanilide derivatives UC781,(N-[4-chloro-3-(3-methyl-2-butenyloxy)pheny1]-2-methyl-3-furancarbothiomide), is a extremely potent inhibitor of human immunodeficiency virus type1(HIV-1) reverse transcriptase (RT) with a favorable resistance spectrum. The EC50and SI of UC781inhibited of HIV-1replication in cell culture were0.002μM and50000, respectively. UC781targeted HIV-1RT and had extremely low and almost similar EC50values against wild-type HIV-1and a series of mutant viruses in their RT and restored the anti viral activity of AZT to AZT resistant HIV-1strains. Based on the general crystal structure of the HIV-1RT complexed with NNRTIs, which is like a "butterfly"type, and furthermore,2,3-diaryl-1,3-thiazolidin-4-one and UC-781are served as templates, and according to the general principle of bioisosteric replacement in medicinal chemistry, we designed and synthesized a series of novel2,3-diaryl-1,3-thiazolidin-4-one derivatives in which the2,6-dihalophenyl ring at C-2was retained as an essential moiety, whereas the pyridine ring was replaced by a suitably substituted benzene ring. All the newly compounds are screened for anti-HIV activity in vitro. The results showed that some compunds exhibited inhibition against HIV-1replication, Structure-activity relationship analysis revealed that the different substitute aromatic ring played an important role in affecting the anti-HIV activities. Structure-activity relation was discussed and some useful information was obtained in the design and development of new HIV-1NNRTIs.
Among the most representative classes of NNRTIs, DABOs (dihydro-alkylthio-benzyl-oxopyrimidines) occupy a relevant position. Owing to their structures, DABOs can adapt to changes in the binding pocket due to mutations. So DABOs can inhibit the mutation of the target and also inhibit the emergence of drug resistance. Based on computer aided drug design (CADD), we have designed and synthesized novel DABOs derivatives:piperidine-linked S-DABO analogues. We have also used molecular docking to study the relationship between compounds and HIV-1RT, which provide clear guideline and actual activity predicitions for novel HIV-1RT inhibitors. The selected target molecules based on docking results of virtual screening were synthesized. The preliminary activity and cytotoxicity screening of the newly designed and synthesized target compounds S-DABOs for inhibition of HIV-1(strain IIIB), HIV-2(strain ROD) and HIV-1mutant virus strains are in progress.
In summary, taking the DAPYs,2,3-Diaryl-1,3-thiazolidin-4-one derivatives and DABOs NNRTIs as leads, four series of novel NNRTIs were designed and synthesized in this dissertation according to bioisosterism principle. The new, simple, and convenient synthetic approaches to the title compounds were developed, or improved and optimized. Lastly, through biological evaluation, we find many high potent antiviral agents, which are worth further investigation and development. We hope that the knowledge and insight on the NNRTIs research learnt from the work will help a lot on the battle against the virus and benefit human health and life.
引文
[1]http://www.who.int/hiv/data/epi_core_Dec2013_en.png?ua=1
[2]International Committee on Taxonomy of Viruses (2002). "61.0.6. Lentivirus ". National Institutes of Health. Retrieved February 28,2006.International Committee on Taxonomy of Viruses (2002). "61. Retroviridae". National In stitutes of Health. Retrieved February 28,2006.
[3]HIV Sequence Compendium 2013. http://www.hiv.lanl.gov/content/sequence/H IV/COMPENDIUM/2013/sequence2013.pdf
[4]Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD.HIV-1 dyn-amics in vivo:virion clearance rate, infected cell life-span, and viral gene ration time. Science.1996,271 (5255):1582-6.
[5]Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson A S, Ho DD. A novel antiviral intervention results in more accurate assess ment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol.2003,77(8):5037-8.
[6]Zheng YH, Lovsin N, Peterlin BM. Newly identified host factors modulate HIV replication. Immunol. Lett.,2005,97(2):225-34.
[7]Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes S H, Arnold E. Structure and function of HIV-1 reverse transcriptase:molec ular mechanisms of polymerization and inhibition. J. Mol. Biol.,2009,385 (3):693-713.
[8]Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat. Med.,2003,9(7):867-73.
[9]Richman DD.HIV chemotherapy. Nature.2001,410(6831):995-1001.
[10]Yazan E Safadi, Valerie Vivet-Boudou, Roland Marquet. HIV-1 reverse tr anscriptase inhibitors. Appl. Microbiol. Biotechnol.,2007,75,723-737
[11]Jochmans D. Novel HFV-1 reverse transcriptase inhibitors. Virus Res.200 8,134 (1-2):171-85.
[12]Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replicatio n by non-nucleoside reverse transcriptase inhibitors. Virus. Res.,2008,134 (1-2):147-56.
[13]Melikian GL, Rhee SY, Varghese V, Porter D, White K, Taylor J, Towne r W, Troia P, Burack J, Dejesus E, Robbins GK, Razzeca K, Kagan R, L iu TF, Fessel WJ, Israelski D, Shafer RW. Non-nucleoside reverse transcri ptase inhibitor (NNRTI) cross-resistance:implications for preclinical evaluat ion of novel NNRTIs and clinical genotypic resistance testing. J. Antimicr ob. Chemother.,2014,69(1):12-20.
[14]Martins S, Ramos MJ, Fernandes PA. The current status of the NNRTI fa-mily of antiretrovirals used in the HAART regime against HIV infection. Curr. Med. Chem.,2008,15(11):1083-95.
[15]Daar ES. Emerging resistance profiles of newly approved antiretroviral dru gs. Top HIV Med.2008,16,110-116.
[16]Towner WJ, Cassetti Ⅰ, Domingo P, Nijs S, Kakuda TN, Vingerhoets J, Woodfall B. Etravirine:clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resist ance. Antivir. Ther.,2010,15(6):803-16
[17]Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert. Opin. Drug. Saf.,2007,6,147-154
[18]Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV inf-ection.Expert. Opin. Drug. Metab. Toxicol.,2010,6(1):95-103.
[19]Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, Joc hmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. TMC278, a next -generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active ag ainst wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents. Chemothe r.,2010,54(2):718-27
[20]Imaz A, Podzamczer D. The role of rilpivirine in clinical practice:strengt-hs and weaknesses of the new nonnucleoside reverse transcriptase inhibito r for HIV therapy. AIDS Rev.,2012,14(4):268-78.
[21]Das K, Arnold E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Curr. Opin. Virol.,2013,3(2):119-28.
[22]Hsiou Y, Ding J, Das K, Clark AD Jr, Hughes SH, Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution:implications of conformational changes for polymerization and inhibition mechanisms. S tructure.1996,4(7):853-60.
[23]Sarafianos SG, Clark AD Jr, Das K, Tuske S, Birktoft JJ, Ilankumaran P, Ramesha AR, Sayer JM, Jerina DM, Boyer PL, Hughes SH, Arnold E. S tructures of HIV-1 reverse transcriptase with pre- and post-translocation A ZTMP-terminated DNA. EMBO J.2002,21(23):6614-24.
[24]Shen L, Shen J, Luo X, Cheng F, Xu Y, Chen K, Arnold E, Ding J, Jia ng H. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. Biophys. J.2003,84(6):3547-63.
[25]Temiz NA, Bahar I. Inhibitor binding alters the directions of domain moti ons in HIV-1 reverse transcriptase. Proteins.2002,49(l):61-70.
[26]Restle T, Muller B, Goody RS. RNase H activity of HIV reverse transcri-ptases is confined exclusively to the dimeric forms. FEBS Lett.1992,300 (1):97-100.
[27]Larder BA, Stammers DK. Closing in on HIV drug resistance. Nat. Struct. Biol.,1999,6(2):103-6.
[28]Sarafianos SG, Das K, Ding J, Boyer PL, Hughes SH, Arnold E. Touchin g the heart of HIV-1 drug resistance:the fingers close down on the dNTP at the polymerase active site. Chem. Biol.,1999,6(5):137-46.
[29]Nicolas Sluis-Cremer, N. Alpay Temiz, Ivet Bahar. Conformational Change s in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Trans criptase Inhibitor Binding. Curr. HIV Res.,2004,2(4):323-332.
[30]Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R. T.; Balza rini, J.;De Clercq, E. A Novel Lead for Specific Anti-HIV-1 Agents:1-[(2-Hydroxyet hoxy)met hyll-6-(phenylt hio)t hymine. J. Med. Chem.1 989,32,2507-2509
[31]P Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M.; Breslin, H.;Raeymaekers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Sch ellekens, K.; Janssen, M. A. C; De Clercq, E.; Janssen, P. Potent and sel ective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature,1990,343,470-474
[32]Kukla, M.; Breslin, H.; Pauwels, R.; Fedde, C.; Miranda, M.; Scott, M.; Sherrill, R.; Raeymaekers, A.; Van Gelder, J.; Andries, K.; Janssen, M. A. C.; De Clercq, E.;Janssen, P. Synthesis and Anti-HIV-1 Activity of 4,5,6, 7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIB O) Derivatives. J. Med. Chem.1991,34,746-751
[33]Dhaval G. Prajapati, R. Ramajayam, Mange Ram Yadav, Rajani Giridhar. The search for potent, small molecule NNRTIs:A review. Bioorg.\Med. C hem.,2009,17:5744-5762
[34]Ding, J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen,P.A.J., Hughes, S.H., Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse non-nucleoside inhibitors. Nat. Struct. Biol.1995,2,407-415
[35]LA Kohlstaedt, J Wang, JM Friedman, PA Rice, TA Steitz. Crystal structu re at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an in hibitor. Science.1992,256,1783-1790
[36]Reynolds C, de Koning CB, Pelly SC, van Otterlo WA, Bode ML. In sea-rch of a treatment for HIV--current therapies and the role of non-nucleosi de reverse transcriptase inhibitors (NNRTIs). Chem. Soc. Rev.,2012,41(1 3):4657-4670.
[37]Boyer, P.L., Ding, J., Arnold, E., Hughes, S.H. Subunit specificity of mut ations that confer resistance to non-nucleoside inhibitors in human immuno deficiency virus type 1 reverse transcriptase. Antimicrob. Agents. Chemoth er.,1994,38,1909-1914.
[38]Jonckheere, H., Taymans, J.-M., Balzarini, J., Velazquez, S., Camarasa, M.-J., Desmyter, J., De Clercq, E., Anne, J. Resistance of HIV-1 reverse tra nscriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide)] (TSAO) derivatives is determined by the mutati on Glu138→Lys on the p51 subunit. J. Biol. Chem.1994,269,25255-25 258
[39]Rodriguez-Barrios, F., Perez, C., Lobaton, E., Velazquez, S.,Chamorro, C., San-Felix, A., Perez-Perez, M.-J., Camarasa, M.-J., Pelemans, H., Balza rini, J., Gago, F. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-b-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxa thiole-2",2"-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. J. Med. Chem.2001,44,1853-1865
[40]Balzarini, J., Kleim, J.-P., Riess, G., Camarasa, M.-J., De Clercq,E., Karls son, A. Sensitivity of (138 Glu_Lys) mutated human immunodeficiency vir us type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibito rs. Biochem. Biophys. Res. Commun.,1994,201,1305-1312
[41]Camarasa MJ, Velazquez S, San-Felix A, Perez-Perez MJ. TSAO derivativ es the first non-peptide inhibitors of HIV-1 RT dimerization. Antivir. Che m. Chemother.,2005,16(3):147-53.
[42]Esnouf, R.M., Stuart, D.I., De Clercq, E., Schwartz, E., Balzarini, J. Mod els which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. Biochem. Biophys. Res. Commun.1997,23 4,458-464
[43]Ren, J., Esnouf, R.M., Hopkins, A.L., Warren, J., Balzarini, J.,Stuart, D.I., Stammers, D. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry.1998,37,14394-14403
[44]Balzarini J. Current status of the non-nucleoside reverse transcriptase inhib itors of human immunodeficiency virus type 1. Curr. Top Med. Chem.,20 04,4(9):921-44.
[45]Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design o f anti-AIDS drugs:conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhi bitors. Prog. Biophys. Mol. Biol.,2005,88(2):209-31
[46]Ludovici DW, Kukla MJ, Grous PG, Krishnan S, Andries K, de Bethune MP, Azijn H, Pauwels R, De Clercq E, Arnold E, Janssen PA. Evolution of anti-HIV drug candidates. Part 1:From alpha-anilinophenylacetamide (al pha-APA) to imidoyl thiourea (ITU). Bioorg. Med. Chem. Lett.,2001,11 (17):2225-2228
[47]De Corte BL. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodi azepin-2(1H)-one (TIBO) to etravirine (TMC125):fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Che m.,2005,48(6):1689-96
[48]Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koy mans L, Vinkers M, Guillemont J, Pasquier E, Kukla M, Ludovici D, An dries K, de Bethune MP, Pauwels R, Das K, Clark AD Jr, Frenkel YV, Hughes SH, Medaer B, De Knaep F, Bohets H, De Clerck F, Lampo A, Williams P, Stoffels P. In search of a novel anti-HIV drug:multidisciplina ry coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimet hylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem.,2005,48(6):1901-1909
[49]Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ, Hu ghes SH, Arnold E. High-resolution structures of HIV-1 reverse transcripta se/TMC278 complexes:strategic flexibility explains potency against resistan ce mutations. Proc. Natl. Acad. Sci. U S A.,2008,105(5):1466-71
[50]Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, V inkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash R W, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Bethune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E. Roles of con formational and positional adaptability in structure-based design of TMC12 5-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhi bitors that are highly potent and effective against wild-type and drug-resist ant HIV-1 variants. J. Med. Chem.,2004,47(10):2550-60
[51]Das K, Ding J, Hsiou Y, Clark AD Jr, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL, Clark P, Smith RH Jr, Kroeger S mith MB, Michejda CJ, Hughes SH, Arnold E. Crystal structures of 8-C1 and 9-C1 TIBO complexed with wild-type HIV-1 RT and 8-C1 TIBO comp lexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol., 1996,264(5):1085-1100
[52]Lindberg J, Sigurdsson S, Lowgren S, Andersson HO, Sahlberg C, Noreen R, Fridborg K, Zhang H, Unge T. Structural basis for the inhibitory effic acy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem.,2002,269(6):1670-1677
[53]Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK.Structura 1 basis for the resilience of efavirenz (DMP-266) to drug resistance mutati ons in HIV-1 reverse transcriptase. Structure.2000,8(10):1089-1094
[54]Hsiou Y, Das K, Ding J, Clark AD Jr, Kleim JP, Rosner M, Winkler I, Riess G, Hughes SH, Arnold E. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibit or HBY 097:inhibitor flexibility is a useful design feature for reducing dr ug resistance. J. Mol. Biol.,1998,284(2):313-23
[55]Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Stammers D K. Crystal structures of HIV-1 reverse transcriptases mutated at codons 10 0,106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol.,2004,336(3):569-78
[56]Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P, Janssen PA, K leim JP, Rosner M, Hughes SH, Arnold E. The Lys103Asn mutation of H IV-1 RT:a novel mechanism of drug resistance. J. Mol. Biol.,2001,309 (2):437-45.
[57]Udier-Blagovic M, Watkins EK, Tirado-Rives J, Jorgensen WL. Activity p redictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase. Bioorg. Med. Chem. Lett.,2003,13(19):3337-40
[58]Wohrl BM, Krebs R, Thrall SH, Le Grice SF, Scheidig AJ, Goody RS. Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated in th e primer grip region of p66. Implications for DNA synthesis and dimerizat ion. J. Biol. Chem.,1997,272(28):17581-7
[59]Ghosh M, Williams J, Powell MD, Levin JG, Le Grice SF. Mutating a c onserved motif of the HIV-1 reverse transcriptase palm subdomain alters p rimer utilization. Biochemistry.1997,36(19):5758-68
[60]Pelemans H, Esnouf R, De Clercq E, Balzarini J. Mutational analysis of t rp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational desig n of new non-nucleoside RT inhibitors. Mol. Pharmacol.,2000,57(5):954-60
[61]Pelemans H, Esnouf R, Min KL, Parniak M, De Clercq E, Balzarini J. M utations at amino acid positions 63,189, and 396 of human immunodefici ency virus type 1 reverse transcriptase (RT) partially restore the DNA pol ymerase activity of a Trp229Tyr mutant RT. Virology,2001,287(1):143-5 0
[62]Fattorusso C, Gemma S, Butini S, Huleatt P, Catalanotti B, Persico M, D e Angelis M, Fiorini I, Nacci V, Ramunno A, Rodriquez M, Greco G, No vellino E, Bergamini A, Marini S, Coletta M, Maga G, Spadari S, Campia ni G. Specific targeting highly conserved residues in the HIV-1 reverse tra nscriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. J. M ed. Chem.,2005,48(23):7153-65
[1]Ludovici, D.W.; Kavash, R.W.; Kukla, M.J.; Ho, C.Y.; Ye, H.; De Corte, B. L.; Andries, K.; de Bethune, M.-P.; Azijn, H.; Pauwels, R.; Moereels, H.E.; Heeres, J.; Koymans, L.M.; de Jonge, M.R.; Van Aken, K.J.; Daeyaert, F. F.; Lewi, P.J.; Das, K.; Arnold, E.; Janssen, P.A. Evolution of anti-HIV dr ug candidates part 2:diaryltriazine (DATA) analogues. Bioorg. Med. Che m. Lett.,2001,17,2229-2234.
[2]Ludovici, D.W.; De Corte, B.L.; Kukla, M.J.; Ye, H.; Ho, C.Y.; Lichtenstei n, M.A.; Kavash, R.W.; Andries, K.; de Bethune, M.-P.; Azijn, H.; Pauwel s, R.; Lewi, P.J.; Heeres, J.; Koymans, L.M.H.; de Jonge, M.R.; Van Ake n, K.J.A.; Daeyaert, F.F.D.; Das, K.; Arnold, E.; Janssen, P.A.J. Evolution of anti-HIV drug candidates, part 3:diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett.,2001,11,2235-2239.
[3]Andries K1, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Jans sen P, De Corte B, Vingerhoets J, Pauwels R, de Bethune MP.TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active a gainst nonnucleoside reverse transcriptase inhibitor-resistant human immuno deficiency virus type 1. Antimicrob. Agents. Chemother.,2004,48(12):468 0-6.
[4]Janssen, P.A.J.; Lewi, P.J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Lu dovici, D.; Andries, K.; de Bethune, M.-P.; Pauwels, R.; Das, K.; Clark, A.D.; Jr.; Frenkel, Y.V.; Hughes, S.H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a no vel anti-HIV drug:multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2pyrimidinyl]amino]benz onitrile (R278474, rilpivirine). J. Med. Chem.,2005,48,1901-1909.
[5]Guillemont, J.; Pasquier, E.; Palandjian, P.; Vernier, D.; Gaurrand, S.; Lewi, P.J.; Heeres, J.; de Jonge, M.R.; Koymans, L.M.H.; Daeyaert, F.F.D.; Vink ers, M.H.; Arnold, E.; Das, K.; Pauwels, R.; Andries, K.; de Bethune, M.-P.; Bettens, E.; Hertogs, K.; Wigerinck, P.; Timmerman, P.; Janssen, P.A.J. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J. Med. Chem.,2005,48, 2072-2079]
[6]Heeres, J.; Lewi, P.J. The medicinal chemistry of the DATA and DAPY ser ies of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Adv. Antiviral Drug Des.,2007,5,213-242.
[7]Feng, X.Q.; Liang, Y.H.; Zeng, Z.S.; Chen, F.E.; Balzarini, J.; Pannecouque, C.; De Clercq, E. Structural modifications of DAPY analogues with potent anti-HIV-1 activity. Chem. Med. Chem.,2009,4,219-224.
[8]Liang, Y.H.; Feng, X.Q.; Zeng, Z.S.; Chen, F.E.; Balzarini, J.; Pannecouque C.; De Clercq, E. Design, synthesis, and SAR of naphthyl-substituted diary lpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Ch em. Med. Chem.,2009,4,1537-1545.
[9]Liang, Y.H.; Zeng, Z.S.; Liu, Z.Q.; Feng, X.Q.; Chen, F.E.; Balzarini, J.; P annecouque, C.; De Clercq, E. Synthesis and anti-HIV activity of 2-naphth yl substituted DAPY analogues as non-nucleoside reverse transcriptase inhi bitors. Bioorg. Med. Chem.,2010,18(13):4601-5
[10]Di Fabio, S.; Van Roey, J.; Giannini, G.; van den Mooter, G.; Spada, M.; Binelli, A.; Pirillo, M.F.; Germinario, E.; Belardelli, F.; de Bethune, M.-P.; Vella, S. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formula tion. AIDS,2003,17,1597-1604.
[11]Van Herrewege, Y.; Vanham, G.; Michiels, J.; Fransen, K.; Kestens, L.; A ndries, K.; Janssen, P.; Lewi, P. A series of diaryltriazines and diarylpyrim idines are highly potent non-nucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob. Agents Chemother.,200 4,48,3684-3689.
[12]Feng, X.Q.; Zeng, Z.S.; Liang, Y.H.; Chen, F.E.; Pannecouque, C.; Balzari ni, J.; De Clercq, E. Synthesis and biological evaluation of 4-(hydroxyimin o)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV. Bioorg. Med. Chem.,2010,18,2370-2374.
[13]Zeng, Z.S.; Liang, Y.H.; Feng, X.Q.; Chen, F.E.; Pannecouque, C.; Balzari ni, J.; De Clercq, E. Lead optimization of diarylpyrimidines as non-nucleos ide inhibitors of HIV-1 reverse transcriptase. Chem. Med. Chem.,2010,5, 837-840.
[14]Mordant, C.; Schmitt, B.; Pasquier, E.; Demestre, C.; Queguiner, L.; Masu ngi, C.; Peeters, A.; Smeulders, L.; Bettens, E.; Hertogs, K.; Heeres, J.; L ewi, P.; Guillemont J. Synthesis of novel diarylpyrimidine analogues of T MC278 and their antiviral activity against HIV-1 wild-type and mutant stra ins. Eur. J. Med. Chem.,2007,42,567-579.
[15]Girardet, J.L.; Koh, Y.H.; Shaw, S.; Kin, H.W. Diaryl-purine, azapurines a nd- deazapurines as non-nucleoside reverse transcriptase inhibitors for treat ment of HIV. WO 2006122003,2006.
[16]Udier-Blagovic, M.; Tirado-Rives, J.; Jorgensen, W.L. Validation of a mod-el for the complex of HIV-1 reverse transcriptase with non-nucleoside inh ibitor TMC125. J. Am. Chem. Soc.,2003,125,6016-6017.
[17]Lansdon, E.B.; Brendza, K.M.; Hung, M.; Wang, R.; Mukund, S.; Jin, D.; Birkus, G.; Kutty, N.; Liu, X.H. Crystal structures of HIV-1 reverse transcr-iptase with etravirine (TMC125) and rilpivirine (TMC278):implications fo r drug design. J. Med. Chem.,2010,53,4295-4299.
[18]Lansdon, E.B.; Brendza, K.M.; Hung, M.; Wang, R.; Mukund, S.; Jin, D.; Birkus, G.; Kutty, N.; Liu, X.H. Crystal structures of HIV-1 reverse transcr-iptase with etravirine (TMC125) and rilpivirine (TMC278):implications fo r drug design. J. Med. Chem.,2010,53,4295-4299.
[19]Kertesz, D.J.; Brotherton-Pleiss, C.; Yang, M.M.; Wang, Z.G.; Lin, X.F.; Q iu, Z.X.; Hirschfeld, D.R.; Gleason, S.; Mirzadegan, T.; Dunten, P.W.; Harr is, S.F.; Villasenor, A.G.; Hang, J.Q.; Heilek, G.M.; Klumpp, K. Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. Bioorg. Med. Chem. Lett.,2010,20,4215-4218.
[20]Tang, G.; Kertesz, D.J.; Yang, M.; Lin, X.; Wang, Z.; Li, W; Qiu, Z.; C hen, J.; Mei, J.; Chen, L.; Mirzadegan, T.; Harris, S.F.; Villasenor, A.G.; F retland, J.; Fitch, W.L.; Hang, J.Q.; Heilek, G.; Klumpp, K. Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses. Bioorg. Med. Chem. Lett.,2010,20,6020-6023.
[21]Brotherton-Pleiss, C.E.; Kertesz, D.J.; Yang, M.M. Non-nucleoside reverse transcriptase inhibitors. WO 2008071587,2008.
[22]Zhan, P.; Liu, X.Y.; Li, Z.Y.; Pannecouque, C.; De Clercq, E. Design strat egies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem.,2 009,16,3903-3917.
[23]Morphy, R.; Rankovic, Z. Designing multiple ligands-medicinal chemistry strategies and challenges. Curr. Pharm. Des.,2009,15,587-600.
[24]Zhan, P.; Liu, X.Y. Designed multiple ligands:an emerging anti-HIV drug discovery paradigm. Curr. Pharm. Des.,2009,15,1893-1917.
[1]Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Zappala, M., Anti-HIV agents. I:synthesis and in vitro anti-HIV evaluation of novel 1H,3H-t hiazolo[3,4-a]benzimidazoles. Farmaco,1991,46, (6),817-823.
[2]Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Zappala, M., Anti-HIV agents Ⅱ. synthesis and in vitro anti-HIV activity of novel 1H,3H-thi azolo[3,4-a]benzimidazoles. Farmaco,1991,46, (7-8),925-933.
[3]Chimirri, A.; Grasso, S.; Molica, C.; Monforte, A.M.; Monforte, P.; Zappal a, M.; Bruno, G.; Nicolo, F.; Witvrouw, M.; Jonckeere, H.; Balzarini, J.; De Clercq, E., Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2',6'-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidiazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibi tor. Antivir.Chem.Chemother,1997,8,363-370.
[4]McMartin, C.; Bohacek, R.S., QXP:Powerful, rapid computer algorithms fo r structure-based drug design. J. Comput. Aided Mol. Des.,1997,11, (4), 333-344.
[5]Barreca, M.L.; Carotti, A.; Carrieri, A.; Chimirri, A.; Monforte, A.M.; Pelle grini Calace, M.; Rao, A., Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorg. Med. Chem.,1999,7, (11),2283-2292.
[6]Barreca, M.L.; Chimirri, A.; De Luca, L.; Monforte, A.-M.; Monforte, P.; Rao, A.; Zappala, M.; Balzarini, J.; De Clercq, E.; Pannecouque, C.; Witv rouw, M., Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg. Med. Chem. Lett.,2001,11, (13),1793-1796.
[7]Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Rao, A.; Zappala, M.; Bruno, G.; Nicolo, F.; Scopelliti, R., Anti-HIV agents. V. Synthesis, st ructure and in vitro anti-HIV activity of novel 1H,3H-naphtho[2',3':4,5]i midazo[1,2-c]thiazoles. Farmaco,1997,52, (11),673-677.
[8]Roth, T.; Morningstar, M.L.; Boyer, P.L.; Hughes, S.H.; Buckheit, R.W.; Mi chejda, C.J., Synthesis and biological activity of novel nonnucleoside inhibi tors of HIV-1 reverse transcriptase.2-Aryl-substituted benzimidazoles. J. M ed. Chem.,1997,40, (26),4199-4207.
[9]Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Rao, A.; Zappala, M.; Bruno, G.; Nicolo, F.; Pannecouque, C; Witvrouw, M.; De Clercq, E., Synthesis, structure and in vitro anti-human immunodeficiency virus activi ty of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles. Antivir. Chem. C hemother.,1998,9, (5),431-438.
[10]Chimirri, A.; Grasso, S.; Monforte, P.; Rao, A.; Zappala, M.; Monforte, A. M.; Pannecouque, C.; Witvrouw, M.; Balzarini, J.; De Clercq, E., Synthesi s and biological activity of novel 1H,3H-thiazolo[3,4-a] benzimidazoles:no n-nucleoside human immunodeficiency virus type 1 reverse transcriptase in hibitors. Antivir. Chem. Chemother.,1999,10, (4),211-217.
[11]Chimirri, A.; Monforte, A.M.; Monforte, P.; Nicolo, F.; Rao, A.; Zappala, M., Synthesis and structural features of new cyclofunctionalized benzimidaz oles. Heterocycles,2000,53, (3),613-620.
[12]Chimirri, A.; Monforte, P.; Rao, A.; Zappala, M.; Monforte, A.M.; De Sar ro, G.; Pannecouque, C.; Witvrouw, M.; Balzarini, J.; De Clercq, E., Synth esis, biological activity, pharmacokinetic properties and molecular modelling studies of novel 1H,3H-oxazolo[3,4-a]benzimidazoles:non-nucleoside HIV-1 reverse transcriptase inhibitors. Antivir Chem Chemother,2001,12, (3), 169-174.
[13]Rao, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pann ecouque, C.; Zappala, M., Synthesis and anti-HIV activity of 1-(2,6-difluor ophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substitut ed benzimidazoles. Ⅱ Farmaco,2002,57, (10),819-823.
[14]Barreca, M.L.; Rao, A.; De Luca, L.; Zappala, M.; Monforte, A.M.; Maga, G.; Pannecouque, C.; Balzarini, J.; De Clercq, E.; Chimirri, A.; Monforte, P., Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J. Med. Chem.,2005,48, (9),3433-3437.
[15]Barreca, M.L.; Chimirri, A.; De Clercq, E.; De Luca, L.; Monforte, A.-M.; Monforte, P.; Rao, A.; Zappala, M., Anti-HIV agents:design and discove ry of new potent RT inhibitors. Ⅱ Farmaco,2003,58, (3),259-263.
[16]Barreca, M.L.; Balzarini, J.; Chimirri, A.; De Clercq, E.; De Luca, L.; Ho ltje, H.D.; Holtje, M.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Ra o, A.; Zappala, M., Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent ant i-HIV agents. J. Med. Chem.,2002,45, (24),5410-5413.
[17]Rawal, R.K.; Tripathi, R.K.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Synthesis and biological evaluation of 2,3-diaryl substituted-1,3-thiazolidin-4-ones as anti-HIV agents. Medicinal Chemistry,2007,3, (4),355-363.
[18]Rao, A.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monf orte, P.; Pannecouque, C.; Zappala, M., Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Ⅱ Farmaco,2003,58, (2),115-120.
[19]Murugesan, V.; Tiwari, VS.; Saxena, R.; Tripathi, R.; Paranjape, R.; Kulka rni, S.; Makwana, N.; Suryawanshi, R.; Katti, S.B., Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside rever se transcriptase inhibitors. Bioorg. Med. Chem.,2011,19, (22),6919-6926.
[20]Rao, A.; Balzarini, J.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Zappala, M.,2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse tran scriptase inhibitors. Antiviral Res.,2004,63, (2),79-84.
[21]Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Sy nthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents. Bioorg. Med. Chem.,2007,15, (9), 3134-3142.
[22]Prabhakar, Y.S.; Solomon, V.R.; Rawal, R.K.; Gupta, M.K.; Katti, S.B., C P-MLR/PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Qsar & Combinatorial Science, 2004,23, (4),234-244.
[23]Prabhakar, Y.S.; Rawal, R.K.; Gupta, M.K.; Solomon, V.R.; Katti, S.B., To pological descriptors in modeling the HIV inhibitory activity of 2-aryl-3-p yridyl-thiazolidin-4-ones. Combinatorial Chemistry & High Throughput Scre ening,2005,8, (5),431-437.
[24]Roy, K.; Leonard, J.T., Classical QSAR modeling of anti-HIV 2,3-diaryl-1, 3-thiazolidin-4-ones. Qsar & Combinatorial Science,2005,-24, (5),579-59 2.
[25]Chen, H.; Bai, J.; Jiao, L.L.; Guo, Z.H.; Yin, Q.M.; Li, X.L., Design, mi crowave-assisted synthesis and HIV-RT inhibitory activity of 2-(2,6-dihalop henyl)-3-(4,6-dimethyl-5-(un)substituted-pyrimidin-2-yl)thiazolidin-4-ones. Bio org. Med. Chem.,2009,17, (11),3980-3986.
[26]Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., D esign, synthesis, and evaluation of 2-aryl-3-heteroaryl-l,13-thiazolidin-4-ones as anti-HIV agents. Bioorg. Med. Chem.,2007,15, (4),1725-1731.
[27]Rawal, R.K.; Prabhakar, Y.S.; Katti, S.B.; De Clercq, E.,2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors. Bioorg. Med. Chem.,2005,13, (24),6771-6776.
[28]Rawal, R.K.; Tripathi, R.; Kulkarni, S.; Paranjape, R.; Katti, S.B.; Pannec ouque, C.; De Clercq, E.,2-(2,6-dihalo-phenyl)-3-heteroaryl-2-ylmethyl-1,3-thiazolidin-4-ones:anti-HIV agents. Chemical Biology & Drug Design,200 8,72, (2),147-154.
[29]Rawal, R.K.; Solomon, V.R.; Prabhakar, Y.S.; Katti, S.B.; De Clercq, E., Synthesis and QSAR studies on thiazolidinones as anti-HIV agents. Combi natorial Chemistry & High Throughput Screening,2005,8, (5),439-443.
[30]Rao, A.; Balzarini, J.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pannecouque, C; Zappala, M., Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Ⅱ Farmaco,2004,59, (1), 33-39.
[31]Rawal, R.K.; Prabhakar, Y.S.; Katti, S.B., Molecular surface features in m odeling the HIV-1 RT inhibitory activity of 2-(2,6-disubstituted phenyl)-3-(s ubstituted pyrimidin-2-yl)-thiazolidin-4-ones. Qsar & Combinatorial Science, 2007,26, (3),398-406.
[32]Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., D esign and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-o nes as anti-HIV agents. European Journal of Medicinal Chemistry,2008,4 3, (12),2800-2806.
[33]Rao, A.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monf orte, P.; Pannecouque, C.; Zappala, M., Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Ⅱ Farmaco,2002,57, (9), 747-751
[1]D'Cruz, O. J.; Uckun, F. M. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Enzyme I nhib. Med. Chem.,2006,21 (4),329-350.
[2]Menendez-Arias, L. Molecular basis of human immunodeficiency virus drug resistance:An update. Antiviral Res.,2010,85(1),210-231.
[3]Samuele, A.; Facchini, M.; Rotili, D.; Mai, A.; Artico, M.; Armand-Ugon, M.; Este, J. A.; Maga, G Substrate-induced stable enzyme-inhibitor comple x formation allows tight binding of novel 2-aminopyrimidin-4(3H)-ones to drug-resistant HIV-1 reverse transcriptase mutants. Chem. Med. Chem.,20 08,3(9),1412-1418.
[4]Mai, A.; Artico, M.; Ragno, R.; Sbardella, G.; Massa, S.; Musiu, C.; Mura, M.; Marturana, F.; Cadeddu, A.; Maga, G.; La Colla, P.5-Alkyl-2-alkyla mino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new seri es of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family. Bioorg. Med. Chem.,2005,13,2065-207 7.
[5]M. Botta, M. Artico, S. Massa, A. Gambacorta, M. Marongiu,A. Pani, P. L a Colla. Synthesis, antimicrobial and antiviral activities of isotrimethoprim and some related derivatives. Eur. J. Med. Chem.,1992,27,251-257.
[6]Artico, M.; Massa, S.; Mai, A.; Marongiu, M. E.; Piras, G.; Tramontano, E.; La Colla, P.3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): A New Class of Specific Inhibitors of Human Immunodeficiency Virus Ty pe 1. Antiviral Chem. Chemother.,1993,4,361-368.
[7]Yang S, Chen FE, De Clercq E. Dihydro-alkoxyl-benzyl-oxopyrimidine deri vatives (DABOs) as non-nucleoside reverse transcriptase inhibitors:an upda te review (2001-2011).Curr. Med. Chem.,2012,19(2):152-62.
[8]Erk N. Studies on veterinary manuscripts in Turkey and three samples fro m the 9th,12th and 14th centuries. Hist. Med. Vet.,2002,27(1-4):159-75.
[9]Yu M, Fan E, Wu J, Liu X. Recent advances in the DABOs family as pot ent HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Med. Che m.,2011,18(16):2376-85.
[10]Tramontano, E.; Marongiu, M. E.; De Montis, A.; Loi, A. G.;Artico, M.; Massa, S.; Mai, A.; La Colla, P. Characterization of the Anti-HIV-1 Activi ty of 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), New Non-Nucleoside Reverse Transcriptase Inhibitors. New Microbiol.,1994,17,269-279.
[11]Massa, S.; Mai, A.; Artico, M.; Sbardella, G.; Tramontano, E.;Loi, A. G.; Scano, P.; La Colla, P. Synthesis and Antiviral Activity of New 3,4-Dihyd ro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), Specific Inhibitors of Hu man Immunodeficiency Virus Type-1. Antivir. Chem. Chemother.,1995,6, 1-8.
[12]Mai, A.; Artico, M.; Sbardella, G.; Massa, S.; Loi, A. G.; Tramontano, E.; Scano, P.; La Colla, P. Synthesis and anti-HIV-1 activity of thio analogue s of dihydroalkoxybenzyl oxopyrimidines. J. Med. Chem.,1995,38,3258-3263.
[13]Sudbeck E A, Mao C, Vig R, Venkatachalam TK, Tuel-Ahlqren L, et al. Structure-Based Design of Novel Dihydro-alkoxybenzyloxopyrimidine Deri vatives as Potent Nonnucleoside Inhibitors of the Human Immunodeficienc y Virus Reverse Transcriptase. Antimicrob Agents Chemother,1998,42(12): 3225-3233.
[14]Vig R, Mao C, Venkatachalam T K, Tuel-Ahlqren L, Sudbeck EA, et al. 5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as pote nt non-nucleoside reverse transcriptase inhibitors of S-DABO series. Bioorg. Chem. Lett.,1998,8(12):1461-1466.
[15]Manetti F, Este JA, Clotet-Codina I, Armand-Ugon M, Maga G., et al. Par allel solution-phase and microwave-assisted synthesis of new S-DABO deri vatives endowed with subnanomolar anti-HIV-1 activity. J. Med. Chem.,20 05,48(25):8000-8008.
[16]Togninelli, A.; Carmi, C.; Petricci, E.; Mugnain,i C.; Massa, S.; Corelli, F.; Botta, M. Solution-phase parallel synthesis of S-DABO analogues. Tet rahedron Letters,2006,47,65-67.
[17]Wang, Y. P.; Chen. F. E.; De Clercq, E.; Balzarini, J.; Pannecouque, C. S ynthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-s ubstituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem.,2009,44,1016-1023.
[18]He, Y.; Chen, F.; Sun, G.; Wang, Y.; De Clercq, E.; Balzarini, J.; Pannec ouque, C.5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylm ethyl) pyrimidin- 4(3H)-ones as an unique HIV reverse transcriptase inhibit ors of S-DABO series. Bioorg. Med. Chem. Lett.,2004,14,3173-3176.
[19]He, Y.; Chen, F.; Yu, X.; Wang, Y.; De Clercq, E.; Balzarini, J.; Panneco uque, C. Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synt hesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl) thio]-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones. Bioorg. Chem.,2004,32, 536-548.
[20]Buckheit, R.W. Jr.; Watson, K.; Fliakas-Boltz, V.; Russell, J.; Loftus, T. L.; Osterling, M. C.; Turpin, J. A.; Pallansch, L. A.; White, E.L.; Lee, J. W.; Lee, S. H.; Oh, J. W.; Kwon, H. S.; Chung, S. G.; Cho, E.H.SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother,2001,45,393-400.
[21]Wang, Y. P.; Chen, F. E.; De Clercq, E.; Balzarini, J.; Pannecouque, C. S ynthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarb onylmethylthio) pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 rever se transcriptase inhibitors. Bioorg. Med. Chem.,2008,16,3887-3894.
[22]Hopkins, A. L.; Ren, J. S.; Milton, J.; Hazen, R. J.; Chan, J. H.; Stuart, D. I.; Stammers, D. K. Design of non-nucleoside inhibitors of HIV-1 rev erse transcriptase with improved drug resistance properties.1. J. Med. Che m.,2004,47,5912-5922.
[23]Nawrozkij, M. B.; Rotili, D.; Tarantino, D.; Botta, G.; Eremiychuk, A. S.; Musmuca, I.; Ragno, R.; Samuele, A.; Zanoli, S.; Armand-Ugon, M.; Clo tet-Codina, I.; Novakov, I. A.; Orlinson, B. S.; Maga, G.; Este, J. A.; Arti co, M.; Mai, A.; 5-Alkyl-6- benzyl- 2-(2-oxo- 2-phenylethylsulfanyl) pyri midin- 4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-ben zyl-oxopyrimidine family with peculiar structure-activity relationship profile. J. Med. Chem.,2008,51,4641-4652.
[24]Yu, M.; Liu, X.; Li, Z.; Liu, S.; Pannecouque, C.; De Clercq, E. Synthesi s and biological evaluation of novel 2-(substituted phenylaminocarbonylmet hylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTI s. Bioorg. Med. Chem.,2009,17,7749-7754.
[25]Yu M, Li Z, Liu S, Fan E, Pannecouque C, De Clercq E, Liu X. Synthe sis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbony lmethylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Chem.Med.Che m.,2011,6(5):826-33.
[26]Beroza P, Suto MJ. Designing chiral libraries for drug discovery. Drug. Di scov. Today,2000,5(8):364-372.
[27]Quaglia M, Mai A, Sbardella G, Artico M, Ragno R, et al. Chiral resoluti on and molecular modeling investigation of rac-2-cyclopentylthio-6-[1-(2,6-d ifluorophenyl)ethyl]-3,4-dihydro-5-methylpyrimid in-4(3H)-one (MC-1047), a potent anti-HIV-1 reverse transcriptase agent of the DABO class. Chirality, 2001,13(2):75-80.
[28]Cirilli R, Ferretti R, La Torre F, Borioni A, Fares V, et al. Chiral HPLC separation and absolute configuration of novel S-DABO derivatives. Chirali ty,2009,21(6):604-612.
[29]Radi M, Maga G, Alongi M, Angeli L, Samuele A, et al. Discovery of c hiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivati ves as potent HIV-1 reverse transcriptase inhibitors with high activity agai nst clinically relevant mutants. J. Med. Chem.,2009,52(3):840-851.
[30]Pedersen O S, Petersen L, Brandt M, Pedersen CN EB. Synthesis of 5-Al kyl-6-arylmethyl-2-(7-bromo-3,5-dioxaheptylthio)-pyrimidin-4(1 H)-ones and 7-Oxopyrimidino-1,5,3-oxathiazepines as New S-DABO Analogues with A nti-HIV Activity. Monatshefte. Fur. Chemie.,1999,130(12):1499-1512.
[31]Sbardella G, Mai A, Artico M, Chimenti P, Massa S, et al. Structure-activ ity relationship studies on new DABOS:effect of substitutions at pyrimidi ne C-5 and C-6 positions on anti-HIV-1 activity. Antivir. Chem. Chemothe r.,2001,12(1):37-50.
[32]Mai A, Artico M, Sbaredella G, Massa S, Novellino E, et al.5-Alkyl-2-(alkylthio)- 6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin- 4(3H)- ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. J. Med. Chem.,1999,42(4):619-627.
[33]Mai A, Sbaredella G, Artico M, Ragno R, Massa S, et al. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5- alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem.,2001,44(16):2544-2554.
[34]Mai A, Artico M, Sbardella G, Quartarone S, Massa S, Loi AG, De Mont is A, Scintu F, Putzolu M, La Colla P. Dihydro(alkylthio)(naphthylmethyl)o xopyrimidines:novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. J. Med. Chem.,1997,40(10):1447-54.
[35]Ji L, Chen FE, De Clercq E, Balzarini J, Pannecouque C. Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl or a-c yanoarylmethyl)-3,4- dihydropyrimidin-4(3H)-ones as Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. J.Med.Chem,2007,50(8):1778-17 86.
[36]Nawrozkij MB, Rotili D, Tarantino D, Botta G, Eremiychuk AS, et al.5- Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a seri es of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile. J. Med. Chem.,2008, 51(15):4641-4652.
[37]Qin H, Liu C, Guo Y, Wang R, Zhang J, Ma L, Zhang Z, Wang X, Cui Y, Liu J. Synthesis and biological evaluation of novel C5 halogen-functio nalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhib itors. Bioorg. Med. Chem.,2010,18(9):3231-7.
[1]Das, K.; Clark, A.D.; Lewi, P.J.; Heeres, J.; De Jonge, M.R.; Koymans, L. M.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J.; De Corte, B.; Kavash, R.W.; Ho, C.Y.; Ye, H.; Lichtenstein, M.A.; Andries, K.; Pau wels, R.; de Bethune, M.-P.; Boyer, P.L.; Clark, P.; Hughes, S.H.; Janssen, P.A.; Arnold, E. Roles of conformational and positional adaptability in str ucture-based design of TMC125-R165335 (etravirine) and related non-nucle oside reverse transcriptase inhibitors that are highly potent and effective ag ainst wild-type and drug-resistant HIV-1 variants. J. Med. Chem.,2004,47, 2550-2560.
[2]Lansdon, E.B.; Brendza, K.M.; Hung, M.; Wang, R.; Mukund, S.; Jin, D.; Birkus, G.; Kutty, N.; Liu, X.H. Crystal structures of HIV-1 reverse transcr iptase with etravirine (TMC125) and rilpivirine (TMC278):implications for drug design. J. Med. Chem.,2010,53,4295-4299.
[3]Das, K.; Bauman, J.D., Clark Jr., A.D., Frenkel, Y.V., Lewi, P.J., Shatkin, A.J., Hughes, S.H., Arnold, E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes:strategic flexibility explains potency again st resistance mutations. Proc. Natl. Acad. Sci. USA,2008,105,1466-71.
[4]Udier-Blagovic, M.; Tirado-Rives, J.; Jorgensen, W.L. Validation of a model for the complex of HIV-1 reverse transcriptase with non-nucleoside inhibi tor TMC125. J. Am. Chem. Soc.,2003,125,6016-6017.
[5]Zhan, P. Liu, X.Y.; Li, Z.Y.; Pannecouque, C.; De Clercq, E. Design strate gies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem.,20 09,16,3903-3917.
[6]Fattorusso, C.; Gemma, S.; Butini, S.; Huleatt, P.; Catalanotti, B.; Persico, M.; De Angelis, M.; Fiorini, I.; Nacci, V.; Ramunno, A.; Rodriquez, M.; Greco, G.; Novellino, E.; Bergamini, A.; Marini, S.; Coletta, M.; Maga, G.; Spadari, S.; Campiani, G. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region.design, synthesis, and bi ological evaluation of novel, potent, and broad spectrum NNRTIs with anti viral activity. J. Med. Chem.,2005,48,7153-7165.
[7]Butini, S.; Brindisi, M.; Cosconati, S.; Marinelli, L.; Borrelli, G.; Coccone, S.S.; Ramunno, A.; Campiani, G.; Novellino, E.; Zanoli, S.; Samuele, A.; Giorgi, G.; Bergamini, A.; Mattia, M.D.; Lalli, S.; Galletti, B.; Gemma, S.; Maga, G. Specific targeting of highly conserved residues in the HIV-1 re verse transcriptase primer grip region.2. stereoselective interaction to over come the effects of drug resistant mutations. J. Med. Chem.,2009,52,12 24-1228.
[8]Ren, J.; Nichols, C.; Bird, L.E.; Fujiwara, T.; Sugimoto, H.; Stuart, D.I.; St ammers, D.K. Binding of the second generation nonnucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydroge n bonding. J. Biol. Chem.,2000,275,14316-14320.
[9]Fang, C.; Bauman, J.D.; Das, K.; Remorino, A.; Arnold, E.; Hochstrasser, R.M. Two dimensional infrared spectra reveal relaxation of the non-nucleos ide inhibitor TMC278 complexed with HIV-1 reverse transcriptase. Proc. N atl. Acad. Sci. USA,2008,105,1472-1477.
[10]Hopkins, A.L.; Ren, J.; Milton, J.; Hazen, R.J.; Chan, J.H.; Stuart, D.I.; S tammers, D.K. Design of non-nucleoside inhibitors of HIV-1 reverse transc riptase with improved drug resistance properties 1. J. Med. Chem.,2004, 47,5912-5922.
[11]Hopkins, A.L.; Ren, J.; Esnouf, R.M.; Willcox, B.E.; Jones, E.Y.; Ross, C.; Miyasaka, T.; Walker, R.T.; Tanaka, H.; Stammers, D.K.; Stuart, D.I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT seri es reveal conformational changes relevant to the design of potent non-nucl eoside inhibitors. J. Med. Chem.,1996,39,1589-1600.
[12]Morphy, R.; Rankovic, Z. Designing multiple ligands-medicinal chemistry strategies and challenges. Curr. Pharm. Des.,2009,15,587-600.
[13]Zhan, P.; Liu, X.Y. Designed multiple ligands:an emerging anti-HIV drug discovery paradigm. Curr. Pharm. Des.,2009,15,1893-1917.
[14]K. D. Vyas, R. Nair, V. K. Jadhav, N. Bhatt, S. K.Deshmukh, P. P. Pansa re, R. K.Singh, A. M. Panandikar, Process for preparation of nitropyridine derivatives. WO2010089773.
[15]S. Bahceci, B. Chan, D. S. Chan, J. Chen, T. P. Forsyth, M. Franzini, V. Jammalamadaka, J. W. Jeong, L. R. Jeong, R. M. Kelley, M. H. Kim, J. W. Leahy, M. B. Mac, R. T. Noguchi, P. Rao, B. H. Ridgway, W. Xu, Y. Wang. CDK Modulators. WO2010003133.
[16]Tian X, Qin B, Wu Z, Wang X, Lu H, Morris-Natschke SL, Chen CH, Ji ang S, Lee KH, Xie L. Design, synthesis, and evaluation of diarylpyridine s and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase in hibitors. J Med Chem.,2010,53(23):8287-97.
[17]Jones CD, Andrews DM, Barker AJ, Blades K, Byth KF, Finlay MR, Ge h C, Green CP, Johannsen M, Walker M, Weir HM. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bi oorg. Med. Chem. Lett.,2008,18(24):6486-9.
[18]D. Andrews, M.R. Finlay, C. Green, C. Jones.4-(4-(Imidazol-4-yl) pyrimi din-2-ylamino) benzamides as CDK inhinitors. WO2006064251.
[19]van Rijt SH, Peacock AF, Johnstone RD, Parsons S, Sadler PJ. Organome tallic osmium(II) arene anticancer complexes containing picolinate derivativ es. Inorg. Chem.,2009,48:1753-1762.
[20]D. Varlet, E. Fourmaintraux, P. Depreux, D. Lesieur. Synthesis of 4-[4'-(N, N-Dimethylsulfamoyl)piperazin-1-yl]pyridine Derivatives as Sorbitol Dehydr ogenase Potential Inhibitors. Heterocycles.2000,53:797-804.
[21]K. Wachi, A. Terada. Studies on 1,3-Benzoxazines. I. Synthesis of Prima ry 2-Aminopyridines via the Reaction of Imidoyl Chlorides of 1,3-Benzox azines with Pyridine N-Oxides. Chem. Pharm. Bull.,1980,28:465-472.
[22]M. Wozniak, A. Baranski, B. Szpakiewicz. Regioselectivity of the aminati on of some 3-nitropyridines by liquid ammonia/potassium permanganate. Li ebigs Ann. Chem.,1991,875-878.
[23]N. T. Tzvetkov, C. E. Miiller. Facile synthesis of 5-amino-and 7-amino-6-azaoxindole derivatives. Tetrahedron Lett.,2012,53:5597-5601.
[24]Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq. Rapid and automated tetrazolium-based colori metric assay for the detection of anti-HIV compounds. E. J. Virol. Method s 1988,20,309-321.
[25]Pannecouque, C.; Daelemans, D.; De Clercq, E. Tetrazolium-based colorim etric assay for the detection of HIV replication inhibitors:revisited 20 yea rs later. Nat Protocols.,2008,3,427-434.
[26]Popovic, M.; Sarngadharan, M. G.; Read, E.; Gallo, R. C. Detection, isola tion, and continuous production of cytopathic retroviruses (HTLV-Ⅲ) from patients with AIDS and pre-AIDS. Science 1984,224,497-500.
[27]Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Grest, J.;Dauget,C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Roz enbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retro virus from a patient at risk for acquired immune deficiency syndrome (AIDS). Scienc e 1983,220,868-871.
[28]Miyoshi, I.; Taguchi, H.; Kobonishi, I.; Yoshimoto, S.; Ohtsuki, Y.; Shirais hi, Y.; Akagi, T. Type C virus-producing cell lines derived from adult T c ell leukemia. Gann. Monogr.1982,28,219-228.
[29]Eberle J, Seibl R. A new method for measuring reverse transcriptase acti-vity by ELISA. J. Virol. Methods.,1992,40(3):347-56.
[30]Reverse Transcriptase Assay, Colorimetric Kit, Roche Diagnostics GmbH, Roche. Applied Science, Sandhofer Strasse 116, D-68305 Mannheim, Germ a.
[31]Suzuki K, Craddock BP, Okamoto N, Kano T, Steigbigel RT. Poly A-link ed colorimetric microtiter plate assay for HIV reverse transcriptase. J. Viro 1. Methods.,1993,44(2-3):189-98.
[1]Jan Balzarini, W G Brouwer, D C Dao, E M Osika, Erik De Clercq. Ident ification of Novel Thiocarboxanilide Derivatives That Suppress a Variety of Drug-Resistant Mutant Human Immunodeficiency Virus Type 1 Strains at a Potency Similar to That for Wild-Type Virus. Antimicrob. Agent. Chemo ther.,1996,1454-1466
[2]Balzarini, J., Naesens, L., Verbeken, E., Laga, M., Van Damme, L., Parniak, M., Van Mellaert, L., Anne, J., and De Clercq, E., Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS,1998,12,1129-38
[3]Barnard, J., Borkow, G, and Parniak, M. A., The thiocarboxanilide nonnucl eoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. B iochemistry,1997,36,7786-7792.
[4]Selhorst P, Vazquez AC, Terrazas-Aranda K, Michiels J, Vereecken K, Hey ndrickx L, Weber J, Quiiiones-Mateu ME, Arien KK, Vanham G. Human i mmunodeficiency virus type 1 resistance or cross-resistance to nonnucleosi de reverse transcriptase inhibitors currently under development as microbici des. Antimicrob. Agents. Chemother.,2011,55(4):1403-13.
[5]Bader, J. P., McMahon, J. B., Schultz, R. J., Narayanan, V. L., Pierce, J. B., Harrison, W. A., Weislow, O. S., Midelfort, C. F., Stinson, S. F., and Boyd, M. R., Oxathiin carboxanilide, a potent inhibitor of human immuno deficiency virus reproduction. Proc. Natl. Acad. Sci. U S A,1991,88 (1 5),6740-6744
[6]Balzarini, J., Pelemans, H., Aquaro, S., Perno, C., Witvrouw, M., D, D. S., Clercq, E. D., and Karlsson, A., Highly favorable antiviral activity and re sistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication., Mol. Pharmacol.,1996,50 (2),394-401
[7]Hossain, M. M. and Parniak, M. A., In Vitro Microbicidal Activity of the Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) UC781 against NN RTI-Resistant Human Immunodeficiency Virus Type 1. J. Virol.,2006,80 (9),4440-4446.
[8]Borkow, G, Arion, D., Wainberg, M. A., and Parniak, M. A. The thiocarb oxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azi do-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob. Agents. Chemother.,1999,43 (2),259-263.
[9]Buckheit, R. W., Jr., Snow, M. J., Fliakas-Boltz, V, Kinjerski, T. L., Russe 11, J. D., Pallansch, L. A., Brouwer, W. G, and Yang, S. S., Highly poten t oxathiin carboxanilide derivatives with efficacy against nonnucleoside rev erse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents. Chemother.,1997,41(4),831-837
[10]Borkow, G, Barnard, J., Nguyen, T. M., Belmonte, A., Wainberg, M. A., and Parniak, M. A. Chemical Barriers to Human Immunodeficiency Virus Type 1 (HIV-1) Infection:Retrovirucidal Activity of UC781,a Thiocarboxan ilide Nonnucleoside Inhibitor of HIV-1 Reverse Transcriptase. J. Virol.,19 97,71 (4),3023-3030.
[11]Zussman, A., Lara, L., Lara, H. H., Bentwich, Z., and Borkow, G. Blocki ng of cell-free and cell-associated HIV-1 transmission through human cervi x organ culture with UC781. AIDS.2003,17 (5),653-661.
[12]De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res.,1998,38(3):15 3-79.
[13]Robert M. Esnouf, Stuart, D.I., De Clercq, E., Schwartz, E., Balzarini, J., Models which explain the inhibition of reverse transcriptase by HIV-1-spe cific (thio)carboxanilide derivatives. Biochem. Biophys. Res. Commun.199 7,234,458-464.
[14]Rao GS, Bhatnagar S.In silico structure-based design of a potent, mutation resilient, small peptide inhibitor of HIV-1 reverse transcriptase.J. Biomol. Struct. Dyn.2003,21(2):171-8.
[15]Pelemans H, Esnouf R, De Clercq E, Balzarini J. Mutational analysis of t rp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational desig n of new non-nucleoside RT inhibitors. Mol. Pharmacol.,2000,57(5):954-60.
[16]Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Dar by G, Jones Y, Stuart D and Stammers D, High resolution structures of H Ⅳ-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol.,1995,2:293-302.
[17]Grasso, S.; Chimirri, A.; Monforte, P.; Fenech, G.; Zappala, M.; Monforte, A. M. Compounds with potential antitumor activity. VI--2-Alkyl-3-[2-(1,3, 4-thiadiazolyl)]-4-thiazolidinones. Ⅱ Farmaco.1988,43,851-6
[18]Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappala M.2-(2,6-Dihalophenyl)-3-(pyrimidin -2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase i nhibitors. Antiviral. Res.,2004,63(2):79-84.
[19]Ruiz-Caro J, Basavapathruni A, Kim JT, Bailey CM, Wang L, Anderson KS, Hamilton AD, Jorgensen WL. Optimization of diarylamines as non-nu cleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 2006,16(3):668-71.
[20]Thakur VV, Kim JT, Hamilton AD, Bailey CM, Domaoal RA, Wang L, Anderson KS, Jorgensen WL. Optimization of pyrimidinyl-and triazinyl-a mines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett.,2006,16(21):5664-7.
[1]Samuele A, Facchini M, Rotili D, Mai A, Artico M, Armand-Ugon M, Est e JA, Maga G. Substrate-induced stable enzyme-inhibitor complex formatio n allows tight binding of novel 2-aminopyrimidin-4(3H)-ones to drug-resist ant HIV-1 reverse transcriptase mutants. Chem. Med. Chem.,2008,3(9):14 12-8.
[2]de Brito MA, Rodrigues CR, Cirino JJ, de Alencastro RB, Castro HC, Alb uquerque MG.3D-QSAR CoMFA of a series of DABO derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors. J. Chem. Inf. Model.,20 08,48(8):1706-15.
[3]Mai A, Artico M, Rotili D, Tarantino D, Clotet-Codina I, Armand-Ugon M, Ragno R, Simeoni S, Sbardella G, Nawrozkij MB, Samuele A, Maga G, Este JA. Synthesis and biological properties of novel 2-aminopyrimidin-4(3 H)-ones highly potent against HIV-1 mutant strains. J. Med. Chem.,2007, 50(22):5412-24.
[4]Manetti F, Este JA, Clotet-Codina I, Armand-Uqon M, Maqa G, et al. Para-llel solution-phase and microwave-assisted synthesis of new S-DABO der ivatives endowed with subnanomolar anti-HIV-1 activity. J. Med. Chem.,2 005,48(25):8000-8008
[5]Mai A, Artico M, Ragno R, Sbardella G, Massa S, et al.5-Alkyl-2-alkyla mino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new se ries of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitor s belonging to the DABO family. Bioorg. Med. Chem.,2005,13(6):2065-2077.
[6]Aroyan A A,Kramer M S. Pyrimidine derivatives. Substituted 6-(4'-alkoxy benzyl)pyrimidines. Arm. Khim. Zh.,1971,24(2):161-166.
[7]Riegel B, Lilienfeld W M. The Synthesis of β-Keto Esters by the Decomp-osition of Acylated Malonic Esters. J. Am. Chem. Soc.,1945,67:1273-12 75.
[8]Monostory J. New derivatives on carbon atom 6 of thiouracil with antithyr-oidal effects. An. Asoc. Quim. Argent,1952,40:99-108.
[9]Clay R J, Collom T A, Karrick G L, Wemple K J. A safe, economical me-thod for the preparation of β-oxo ester. Synthesis,1993,290-292.
[10]Hannick S M, Kishi Y. An improved procedure for the Blaise reaction:a short, practical route to the key intermediates ofthe saxitoxin synthesis. J. Org. Chem.,1983,48:3833-3835.
[2]International Committee on Taxonomy of Viruses (2002). "61.0.6. Lentivirus ". National Institutes of Health. Retrieved February 28,2006.International Committee on Taxonomy of Viruses (2002). "61. Retroviridae". National In stitutes of Health. Retrieved February 28,2006.
[3]HIV Sequence Compendium 2013. http://www.hiv.lanl.gov/content/sequence/H IV/COMPENDIUM/2013/sequence2013.pdf
[4]Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD.HIV-1 dyn-amics in vivo:virion clearance rate, infected cell life-span, and viral gene ration time. Science.1996,271 (5255):1582-6.
[5]Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson A S, Ho DD. A novel antiviral intervention results in more accurate assess ment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol.2003,77(8):5037-8.
[6]Zheng YH, Lovsin N, Peterlin BM. Newly identified host factors modulate HIV replication. Immunol. Lett.,2005,97(2):225-34.
[7]Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes S H, Arnold E. Structure and function of HIV-1 reverse transcriptase:molec ular mechanisms of polymerization and inhibition. J. Mol. Biol.,2009,385 (3):693-713.
[8]Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat. Med.,2003,9(7):867-73.
[9]Richman DD.HIV chemotherapy. Nature.2001,410(6831):995-1001.
[10]Yazan E Safadi, Valerie Vivet-Boudou, Roland Marquet. HIV-1 reverse tr anscriptase inhibitors. Appl. Microbiol. Biotechnol.,2007,75,723-737
[11]Jochmans D. Novel HFV-1 reverse transcriptase inhibitors. Virus Res.200 8,134 (1-2):171-85.
[12]Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replicatio n by non-nucleoside reverse transcriptase inhibitors. Virus. Res.,2008,134 (1-2):147-56.
[13]Melikian GL, Rhee SY, Varghese V, Porter D, White K, Taylor J, Towne r W, Troia P, Burack J, Dejesus E, Robbins GK, Razzeca K, Kagan R, L iu TF, Fessel WJ, Israelski D, Shafer RW. Non-nucleoside reverse transcri ptase inhibitor (NNRTI) cross-resistance:implications for preclinical evaluat ion of novel NNRTIs and clinical genotypic resistance testing. J. Antimicr ob. Chemother.,2014,69(1):12-20.
[14]Martins S, Ramos MJ, Fernandes PA. The current status of the NNRTI fa-mily of antiretrovirals used in the HAART regime against HIV infection. Curr. Med. Chem.,2008,15(11):1083-95.
[15]Daar ES. Emerging resistance profiles of newly approved antiretroviral dru gs. Top HIV Med.2008,16,110-116.
[16]Towner WJ, Cassetti Ⅰ, Domingo P, Nijs S, Kakuda TN, Vingerhoets J, Woodfall B. Etravirine:clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resist ance. Antivir. Ther.,2010,15(6):803-16
[17]Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert. Opin. Drug. Saf.,2007,6,147-154
[18]Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV inf-ection.Expert. Opin. Drug. Metab. Toxicol.,2010,6(1):95-103.
[19]Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, Joc hmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. TMC278, a next -generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active ag ainst wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents. Chemothe r.,2010,54(2):718-27
[20]Imaz A, Podzamczer D. The role of rilpivirine in clinical practice:strengt-hs and weaknesses of the new nonnucleoside reverse transcriptase inhibito r for HIV therapy. AIDS Rev.,2012,14(4):268-78.
[21]Das K, Arnold E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Curr. Opin. Virol.,2013,3(2):119-28.
[22]Hsiou Y, Ding J, Das K, Clark AD Jr, Hughes SH, Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution:implications of conformational changes for polymerization and inhibition mechanisms. S tructure.1996,4(7):853-60.
[23]Sarafianos SG, Clark AD Jr, Das K, Tuske S, Birktoft JJ, Ilankumaran P, Ramesha AR, Sayer JM, Jerina DM, Boyer PL, Hughes SH, Arnold E. S tructures of HIV-1 reverse transcriptase with pre- and post-translocation A ZTMP-terminated DNA. EMBO J.2002,21(23):6614-24.
[24]Shen L, Shen J, Luo X, Cheng F, Xu Y, Chen K, Arnold E, Ding J, Jia ng H. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. Biophys. J.2003,84(6):3547-63.
[25]Temiz NA, Bahar I. Inhibitor binding alters the directions of domain moti ons in HIV-1 reverse transcriptase. Proteins.2002,49(l):61-70.
[26]Restle T, Muller B, Goody RS. RNase H activity of HIV reverse transcri-ptases is confined exclusively to the dimeric forms. FEBS Lett.1992,300 (1):97-100.
[27]Larder BA, Stammers DK. Closing in on HIV drug resistance. Nat. Struct. Biol.,1999,6(2):103-6.
[28]Sarafianos SG, Das K, Ding J, Boyer PL, Hughes SH, Arnold E. Touchin g the heart of HIV-1 drug resistance:the fingers close down on the dNTP at the polymerase active site. Chem. Biol.,1999,6(5):137-46.
[29]Nicolas Sluis-Cremer, N. Alpay Temiz, Ivet Bahar. Conformational Change s in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Trans criptase Inhibitor Binding. Curr. HIV Res.,2004,2(4):323-332.
[30]Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R. T.; Balza rini, J.;De Clercq, E. A Novel Lead for Specific Anti-HIV-1 Agents:1-[(2-Hydroxyet hoxy)met hyll-6-(phenylt hio)t hymine. J. Med. Chem.1 989,32,2507-2509
[31]P Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M.; Breslin, H.;Raeymaekers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Sch ellekens, K.; Janssen, M. A. C; De Clercq, E.; Janssen, P. Potent and sel ective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature,1990,343,470-474
[32]Kukla, M.; Breslin, H.; Pauwels, R.; Fedde, C.; Miranda, M.; Scott, M.; Sherrill, R.; Raeymaekers, A.; Van Gelder, J.; Andries, K.; Janssen, M. A. C.; De Clercq, E.;Janssen, P. Synthesis and Anti-HIV-1 Activity of 4,5,6, 7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIB O) Derivatives. J. Med. Chem.1991,34,746-751
[33]Dhaval G. Prajapati, R. Ramajayam, Mange Ram Yadav, Rajani Giridhar. The search for potent, small molecule NNRTIs:A review. Bioorg.\Med. C hem.,2009,17:5744-5762
[34]Ding, J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen,P.A.J., Hughes, S.H., Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse non-nucleoside inhibitors. Nat. Struct. Biol.1995,2,407-415
[35]LA Kohlstaedt, J Wang, JM Friedman, PA Rice, TA Steitz. Crystal structu re at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an in hibitor. Science.1992,256,1783-1790
[36]Reynolds C, de Koning CB, Pelly SC, van Otterlo WA, Bode ML. In sea-rch of a treatment for HIV--current therapies and the role of non-nucleosi de reverse transcriptase inhibitors (NNRTIs). Chem. Soc. Rev.,2012,41(1 3):4657-4670.
[37]Boyer, P.L., Ding, J., Arnold, E., Hughes, S.H. Subunit specificity of mut ations that confer resistance to non-nucleoside inhibitors in human immuno deficiency virus type 1 reverse transcriptase. Antimicrob. Agents. Chemoth er.,1994,38,1909-1914.
[38]Jonckheere, H., Taymans, J.-M., Balzarini, J., Velazquez, S., Camarasa, M.-J., Desmyter, J., De Clercq, E., Anne, J. Resistance of HIV-1 reverse tra nscriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide)] (TSAO) derivatives is determined by the mutati on Glu138→Lys on the p51 subunit. J. Biol. Chem.1994,269,25255-25 258
[39]Rodriguez-Barrios, F., Perez, C., Lobaton, E., Velazquez, S.,Chamorro, C., San-Felix, A., Perez-Perez, M.-J., Camarasa, M.-J., Pelemans, H., Balza rini, J., Gago, F. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-b-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxa thiole-2",2"-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. J. Med. Chem.2001,44,1853-1865
[40]Balzarini, J., Kleim, J.-P., Riess, G., Camarasa, M.-J., De Clercq,E., Karls son, A. Sensitivity of (138 Glu_Lys) mutated human immunodeficiency vir us type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibito rs. Biochem. Biophys. Res. Commun.,1994,201,1305-1312
[41]Camarasa MJ, Velazquez S, San-Felix A, Perez-Perez MJ. TSAO derivativ es the first non-peptide inhibitors of HIV-1 RT dimerization. Antivir. Che m. Chemother.,2005,16(3):147-53.
[42]Esnouf, R.M., Stuart, D.I., De Clercq, E., Schwartz, E., Balzarini, J. Mod els which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. Biochem. Biophys. Res. Commun.1997,23 4,458-464
[43]Ren, J., Esnouf, R.M., Hopkins, A.L., Warren, J., Balzarini, J.,Stuart, D.I., Stammers, D. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry.1998,37,14394-14403
[44]Balzarini J. Current status of the non-nucleoside reverse transcriptase inhib itors of human immunodeficiency virus type 1. Curr. Top Med. Chem.,20 04,4(9):921-44.
[45]Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design o f anti-AIDS drugs:conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhi bitors. Prog. Biophys. Mol. Biol.,2005,88(2):209-31
[46]Ludovici DW, Kukla MJ, Grous PG, Krishnan S, Andries K, de Bethune MP, Azijn H, Pauwels R, De Clercq E, Arnold E, Janssen PA. Evolution of anti-HIV drug candidates. Part 1:From alpha-anilinophenylacetamide (al pha-APA) to imidoyl thiourea (ITU). Bioorg. Med. Chem. Lett.,2001,11 (17):2225-2228
[47]De Corte BL. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodi azepin-2(1H)-one (TIBO) to etravirine (TMC125):fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Che m.,2005,48(6):1689-96
[48]Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koy mans L, Vinkers M, Guillemont J, Pasquier E, Kukla M, Ludovici D, An dries K, de Bethune MP, Pauwels R, Das K, Clark AD Jr, Frenkel YV, Hughes SH, Medaer B, De Knaep F, Bohets H, De Clerck F, Lampo A, Williams P, Stoffels P. In search of a novel anti-HIV drug:multidisciplina ry coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimet hylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem.,2005,48(6):1901-1909
[49]Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ, Hu ghes SH, Arnold E. High-resolution structures of HIV-1 reverse transcripta se/TMC278 complexes:strategic flexibility explains potency against resistan ce mutations. Proc. Natl. Acad. Sci. U S A.,2008,105(5):1466-71
[50]Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, V inkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash R W, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Bethune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E. Roles of con formational and positional adaptability in structure-based design of TMC12 5-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhi bitors that are highly potent and effective against wild-type and drug-resist ant HIV-1 variants. J. Med. Chem.,2004,47(10):2550-60
[51]Das K, Ding J, Hsiou Y, Clark AD Jr, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL, Clark P, Smith RH Jr, Kroeger S mith MB, Michejda CJ, Hughes SH, Arnold E. Crystal structures of 8-C1 and 9-C1 TIBO complexed with wild-type HIV-1 RT and 8-C1 TIBO comp lexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol., 1996,264(5):1085-1100
[52]Lindberg J, Sigurdsson S, Lowgren S, Andersson HO, Sahlberg C, Noreen R, Fridborg K, Zhang H, Unge T. Structural basis for the inhibitory effic acy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem.,2002,269(6):1670-1677
[53]Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK.Structura 1 basis for the resilience of efavirenz (DMP-266) to drug resistance mutati ons in HIV-1 reverse transcriptase. Structure.2000,8(10):1089-1094
[54]Hsiou Y, Das K, Ding J, Clark AD Jr, Kleim JP, Rosner M, Winkler I, Riess G, Hughes SH, Arnold E. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibit or HBY 097:inhibitor flexibility is a useful design feature for reducing dr ug resistance. J. Mol. Biol.,1998,284(2):313-23
[55]Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Stammers D K. Crystal structures of HIV-1 reverse transcriptases mutated at codons 10 0,106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol.,2004,336(3):569-78
[56]Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P, Janssen PA, K leim JP, Rosner M, Hughes SH, Arnold E. The Lys103Asn mutation of H IV-1 RT:a novel mechanism of drug resistance. J. Mol. Biol.,2001,309 (2):437-45.
[57]Udier-Blagovic M, Watkins EK, Tirado-Rives J, Jorgensen WL. Activity p redictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase. Bioorg. Med. Chem. Lett.,2003,13(19):3337-40
[58]Wohrl BM, Krebs R, Thrall SH, Le Grice SF, Scheidig AJ, Goody RS. Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated in th e primer grip region of p66. Implications for DNA synthesis and dimerizat ion. J. Biol. Chem.,1997,272(28):17581-7
[59]Ghosh M, Williams J, Powell MD, Levin JG, Le Grice SF. Mutating a c onserved motif of the HIV-1 reverse transcriptase palm subdomain alters p rimer utilization. Biochemistry.1997,36(19):5758-68
[60]Pelemans H, Esnouf R, De Clercq E, Balzarini J. Mutational analysis of t rp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational desig n of new non-nucleoside RT inhibitors. Mol. Pharmacol.,2000,57(5):954-60
[61]Pelemans H, Esnouf R, Min KL, Parniak M, De Clercq E, Balzarini J. M utations at amino acid positions 63,189, and 396 of human immunodefici ency virus type 1 reverse transcriptase (RT) partially restore the DNA pol ymerase activity of a Trp229Tyr mutant RT. Virology,2001,287(1):143-5 0
[62]Fattorusso C, Gemma S, Butini S, Huleatt P, Catalanotti B, Persico M, D e Angelis M, Fiorini I, Nacci V, Ramunno A, Rodriquez M, Greco G, No vellino E, Bergamini A, Marini S, Coletta M, Maga G, Spadari S, Campia ni G. Specific targeting highly conserved residues in the HIV-1 reverse tra nscriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. J. M ed. Chem.,2005,48(23):7153-65
[1]Ludovici, D.W.; Kavash, R.W.; Kukla, M.J.; Ho, C.Y.; Ye, H.; De Corte, B. L.; Andries, K.; de Bethune, M.-P.; Azijn, H.; Pauwels, R.; Moereels, H.E.; Heeres, J.; Koymans, L.M.; de Jonge, M.R.; Van Aken, K.J.; Daeyaert, F. F.; Lewi, P.J.; Das, K.; Arnold, E.; Janssen, P.A. Evolution of anti-HIV dr ug candidates part 2:diaryltriazine (DATA) analogues. Bioorg. Med. Che m. Lett.,2001,17,2229-2234.
[2]Ludovici, D.W.; De Corte, B.L.; Kukla, M.J.; Ye, H.; Ho, C.Y.; Lichtenstei n, M.A.; Kavash, R.W.; Andries, K.; de Bethune, M.-P.; Azijn, H.; Pauwel s, R.; Lewi, P.J.; Heeres, J.; Koymans, L.M.H.; de Jonge, M.R.; Van Ake n, K.J.A.; Daeyaert, F.F.D.; Das, K.; Arnold, E.; Janssen, P.A.J. Evolution of anti-HIV drug candidates, part 3:diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett.,2001,11,2235-2239.
[3]Andries K1, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Jans sen P, De Corte B, Vingerhoets J, Pauwels R, de Bethune MP.TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active a gainst nonnucleoside reverse transcriptase inhibitor-resistant human immuno deficiency virus type 1. Antimicrob. Agents. Chemother.,2004,48(12):468 0-6.
[4]Janssen, P.A.J.; Lewi, P.J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Lu dovici, D.; Andries, K.; de Bethune, M.-P.; Pauwels, R.; Das, K.; Clark, A.D.; Jr.; Frenkel, Y.V.; Hughes, S.H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a no vel anti-HIV drug:multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2pyrimidinyl]amino]benz onitrile (R278474, rilpivirine). J. Med. Chem.,2005,48,1901-1909.
[5]Guillemont, J.; Pasquier, E.; Palandjian, P.; Vernier, D.; Gaurrand, S.; Lewi, P.J.; Heeres, J.; de Jonge, M.R.; Koymans, L.M.H.; Daeyaert, F.F.D.; Vink ers, M.H.; Arnold, E.; Das, K.; Pauwels, R.; Andries, K.; de Bethune, M.-P.; Bettens, E.; Hertogs, K.; Wigerinck, P.; Timmerman, P.; Janssen, P.A.J. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J. Med. Chem.,2005,48, 2072-2079]
[6]Heeres, J.; Lewi, P.J. The medicinal chemistry of the DATA and DAPY ser ies of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Adv. Antiviral Drug Des.,2007,5,213-242.
[7]Feng, X.Q.; Liang, Y.H.; Zeng, Z.S.; Chen, F.E.; Balzarini, J.; Pannecouque, C.; De Clercq, E. Structural modifications of DAPY analogues with potent anti-HIV-1 activity. Chem. Med. Chem.,2009,4,219-224.
[8]Liang, Y.H.; Feng, X.Q.; Zeng, Z.S.; Chen, F.E.; Balzarini, J.; Pannecouque C.; De Clercq, E. Design, synthesis, and SAR of naphthyl-substituted diary lpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Ch em. Med. Chem.,2009,4,1537-1545.
[9]Liang, Y.H.; Zeng, Z.S.; Liu, Z.Q.; Feng, X.Q.; Chen, F.E.; Balzarini, J.; P annecouque, C.; De Clercq, E. Synthesis and anti-HIV activity of 2-naphth yl substituted DAPY analogues as non-nucleoside reverse transcriptase inhi bitors. Bioorg. Med. Chem.,2010,18(13):4601-5
[10]Di Fabio, S.; Van Roey, J.; Giannini, G.; van den Mooter, G.; Spada, M.; Binelli, A.; Pirillo, M.F.; Germinario, E.; Belardelli, F.; de Bethune, M.-P.; Vella, S. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formula tion. AIDS,2003,17,1597-1604.
[11]Van Herrewege, Y.; Vanham, G.; Michiels, J.; Fransen, K.; Kestens, L.; A ndries, K.; Janssen, P.; Lewi, P. A series of diaryltriazines and diarylpyrim idines are highly potent non-nucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob. Agents Chemother.,200 4,48,3684-3689.
[12]Feng, X.Q.; Zeng, Z.S.; Liang, Y.H.; Chen, F.E.; Pannecouque, C.; Balzari ni, J.; De Clercq, E. Synthesis and biological evaluation of 4-(hydroxyimin o)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV. Bioorg. Med. Chem.,2010,18,2370-2374.
[13]Zeng, Z.S.; Liang, Y.H.; Feng, X.Q.; Chen, F.E.; Pannecouque, C.; Balzari ni, J.; De Clercq, E. Lead optimization of diarylpyrimidines as non-nucleos ide inhibitors of HIV-1 reverse transcriptase. Chem. Med. Chem.,2010,5, 837-840.
[14]Mordant, C.; Schmitt, B.; Pasquier, E.; Demestre, C.; Queguiner, L.; Masu ngi, C.; Peeters, A.; Smeulders, L.; Bettens, E.; Hertogs, K.; Heeres, J.; L ewi, P.; Guillemont J. Synthesis of novel diarylpyrimidine analogues of T MC278 and their antiviral activity against HIV-1 wild-type and mutant stra ins. Eur. J. Med. Chem.,2007,42,567-579.
[15]Girardet, J.L.; Koh, Y.H.; Shaw, S.; Kin, H.W. Diaryl-purine, azapurines a nd- deazapurines as non-nucleoside reverse transcriptase inhibitors for treat ment of HIV. WO 2006122003,2006.
[16]Udier-Blagovic, M.; Tirado-Rives, J.; Jorgensen, W.L. Validation of a mod-el for the complex of HIV-1 reverse transcriptase with non-nucleoside inh ibitor TMC125. J. Am. Chem. Soc.,2003,125,6016-6017.
[17]Lansdon, E.B.; Brendza, K.M.; Hung, M.; Wang, R.; Mukund, S.; Jin, D.; Birkus, G.; Kutty, N.; Liu, X.H. Crystal structures of HIV-1 reverse transcr-iptase with etravirine (TMC125) and rilpivirine (TMC278):implications fo r drug design. J. Med. Chem.,2010,53,4295-4299.
[18]Lansdon, E.B.; Brendza, K.M.; Hung, M.; Wang, R.; Mukund, S.; Jin, D.; Birkus, G.; Kutty, N.; Liu, X.H. Crystal structures of HIV-1 reverse transcr-iptase with etravirine (TMC125) and rilpivirine (TMC278):implications fo r drug design. J. Med. Chem.,2010,53,4295-4299.
[19]Kertesz, D.J.; Brotherton-Pleiss, C.; Yang, M.M.; Wang, Z.G.; Lin, X.F.; Q iu, Z.X.; Hirschfeld, D.R.; Gleason, S.; Mirzadegan, T.; Dunten, P.W.; Harr is, S.F.; Villasenor, A.G.; Hang, J.Q.; Heilek, G.M.; Klumpp, K. Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. Bioorg. Med. Chem. Lett.,2010,20,4215-4218.
[20]Tang, G.; Kertesz, D.J.; Yang, M.; Lin, X.; Wang, Z.; Li, W; Qiu, Z.; C hen, J.; Mei, J.; Chen, L.; Mirzadegan, T.; Harris, S.F.; Villasenor, A.G.; F retland, J.; Fitch, W.L.; Hang, J.Q.; Heilek, G.; Klumpp, K. Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses. Bioorg. Med. Chem. Lett.,2010,20,6020-6023.
[21]Brotherton-Pleiss, C.E.; Kertesz, D.J.; Yang, M.M. Non-nucleoside reverse transcriptase inhibitors. WO 2008071587,2008.
[22]Zhan, P.; Liu, X.Y.; Li, Z.Y.; Pannecouque, C.; De Clercq, E. Design strat egies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem.,2 009,16,3903-3917.
[23]Morphy, R.; Rankovic, Z. Designing multiple ligands-medicinal chemistry strategies and challenges. Curr. Pharm. Des.,2009,15,587-600.
[24]Zhan, P.; Liu, X.Y. Designed multiple ligands:an emerging anti-HIV drug discovery paradigm. Curr. Pharm. Des.,2009,15,1893-1917.
[1]Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Zappala, M., Anti-HIV agents. I:synthesis and in vitro anti-HIV evaluation of novel 1H,3H-t hiazolo[3,4-a]benzimidazoles. Farmaco,1991,46, (6),817-823.
[2]Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Zappala, M., Anti-HIV agents Ⅱ. synthesis and in vitro anti-HIV activity of novel 1H,3H-thi azolo[3,4-a]benzimidazoles. Farmaco,1991,46, (7-8),925-933.
[3]Chimirri, A.; Grasso, S.; Molica, C.; Monforte, A.M.; Monforte, P.; Zappal a, M.; Bruno, G.; Nicolo, F.; Witvrouw, M.; Jonckeere, H.; Balzarini, J.; De Clercq, E., Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2',6'-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidiazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibi tor. Antivir.Chem.Chemother,1997,8,363-370.
[4]McMartin, C.; Bohacek, R.S., QXP:Powerful, rapid computer algorithms fo r structure-based drug design. J. Comput. Aided Mol. Des.,1997,11, (4), 333-344.
[5]Barreca, M.L.; Carotti, A.; Carrieri, A.; Chimirri, A.; Monforte, A.M.; Pelle grini Calace, M.; Rao, A., Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorg. Med. Chem.,1999,7, (11),2283-2292.
[6]Barreca, M.L.; Chimirri, A.; De Luca, L.; Monforte, A.-M.; Monforte, P.; Rao, A.; Zappala, M.; Balzarini, J.; De Clercq, E.; Pannecouque, C.; Witv rouw, M., Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg. Med. Chem. Lett.,2001,11, (13),1793-1796.
[7]Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Rao, A.; Zappala, M.; Bruno, G.; Nicolo, F.; Scopelliti, R., Anti-HIV agents. V. Synthesis, st ructure and in vitro anti-HIV activity of novel 1H,3H-naphtho[2',3':4,5]i midazo[1,2-c]thiazoles. Farmaco,1997,52, (11),673-677.
[8]Roth, T.; Morningstar, M.L.; Boyer, P.L.; Hughes, S.H.; Buckheit, R.W.; Mi chejda, C.J., Synthesis and biological activity of novel nonnucleoside inhibi tors of HIV-1 reverse transcriptase.2-Aryl-substituted benzimidazoles. J. M ed. Chem.,1997,40, (26),4199-4207.
[9]Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Rao, A.; Zappala, M.; Bruno, G.; Nicolo, F.; Pannecouque, C; Witvrouw, M.; De Clercq, E., Synthesis, structure and in vitro anti-human immunodeficiency virus activi ty of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles. Antivir. Chem. C hemother.,1998,9, (5),431-438.
[10]Chimirri, A.; Grasso, S.; Monforte, P.; Rao, A.; Zappala, M.; Monforte, A. M.; Pannecouque, C.; Witvrouw, M.; Balzarini, J.; De Clercq, E., Synthesi s and biological activity of novel 1H,3H-thiazolo[3,4-a] benzimidazoles:no n-nucleoside human immunodeficiency virus type 1 reverse transcriptase in hibitors. Antivir. Chem. Chemother.,1999,10, (4),211-217.
[11]Chimirri, A.; Monforte, A.M.; Monforte, P.; Nicolo, F.; Rao, A.; Zappala, M., Synthesis and structural features of new cyclofunctionalized benzimidaz oles. Heterocycles,2000,53, (3),613-620.
[12]Chimirri, A.; Monforte, P.; Rao, A.; Zappala, M.; Monforte, A.M.; De Sar ro, G.; Pannecouque, C.; Witvrouw, M.; Balzarini, J.; De Clercq, E., Synth esis, biological activity, pharmacokinetic properties and molecular modelling studies of novel 1H,3H-oxazolo[3,4-a]benzimidazoles:non-nucleoside HIV-1 reverse transcriptase inhibitors. Antivir Chem Chemother,2001,12, (3), 169-174.
[13]Rao, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pann ecouque, C.; Zappala, M., Synthesis and anti-HIV activity of 1-(2,6-difluor ophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substitut ed benzimidazoles. Ⅱ Farmaco,2002,57, (10),819-823.
[14]Barreca, M.L.; Rao, A.; De Luca, L.; Zappala, M.; Monforte, A.M.; Maga, G.; Pannecouque, C.; Balzarini, J.; De Clercq, E.; Chimirri, A.; Monforte, P., Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J. Med. Chem.,2005,48, (9),3433-3437.
[15]Barreca, M.L.; Chimirri, A.; De Clercq, E.; De Luca, L.; Monforte, A.-M.; Monforte, P.; Rao, A.; Zappala, M., Anti-HIV agents:design and discove ry of new potent RT inhibitors. Ⅱ Farmaco,2003,58, (3),259-263.
[16]Barreca, M.L.; Balzarini, J.; Chimirri, A.; De Clercq, E.; De Luca, L.; Ho ltje, H.D.; Holtje, M.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Ra o, A.; Zappala, M., Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent ant i-HIV agents. J. Med. Chem.,2002,45, (24),5410-5413.
[17]Rawal, R.K.; Tripathi, R.K.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Synthesis and biological evaluation of 2,3-diaryl substituted-1,3-thiazolidin-4-ones as anti-HIV agents. Medicinal Chemistry,2007,3, (4),355-363.
[18]Rao, A.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monf orte, P.; Pannecouque, C.; Zappala, M., Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Ⅱ Farmaco,2003,58, (2),115-120.
[19]Murugesan, V.; Tiwari, VS.; Saxena, R.; Tripathi, R.; Paranjape, R.; Kulka rni, S.; Makwana, N.; Suryawanshi, R.; Katti, S.B., Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside rever se transcriptase inhibitors. Bioorg. Med. Chem.,2011,19, (22),6919-6926.
[20]Rao, A.; Balzarini, J.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Zappala, M.,2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse tran scriptase inhibitors. Antiviral Res.,2004,63, (2),79-84.
[21]Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Sy nthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents. Bioorg. Med. Chem.,2007,15, (9), 3134-3142.
[22]Prabhakar, Y.S.; Solomon, V.R.; Rawal, R.K.; Gupta, M.K.; Katti, S.B., C P-MLR/PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Qsar & Combinatorial Science, 2004,23, (4),234-244.
[23]Prabhakar, Y.S.; Rawal, R.K.; Gupta, M.K.; Solomon, V.R.; Katti, S.B., To pological descriptors in modeling the HIV inhibitory activity of 2-aryl-3-p yridyl-thiazolidin-4-ones. Combinatorial Chemistry & High Throughput Scre ening,2005,8, (5),431-437.
[24]Roy, K.; Leonard, J.T., Classical QSAR modeling of anti-HIV 2,3-diaryl-1, 3-thiazolidin-4-ones. Qsar & Combinatorial Science,2005,-24, (5),579-59 2.
[25]Chen, H.; Bai, J.; Jiao, L.L.; Guo, Z.H.; Yin, Q.M.; Li, X.L., Design, mi crowave-assisted synthesis and HIV-RT inhibitory activity of 2-(2,6-dihalop henyl)-3-(4,6-dimethyl-5-(un)substituted-pyrimidin-2-yl)thiazolidin-4-ones. Bio org. Med. Chem.,2009,17, (11),3980-3986.
[26]Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., D esign, synthesis, and evaluation of 2-aryl-3-heteroaryl-l,13-thiazolidin-4-ones as anti-HIV agents. Bioorg. Med. Chem.,2007,15, (4),1725-1731.
[27]Rawal, R.K.; Prabhakar, Y.S.; Katti, S.B.; De Clercq, E.,2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors. Bioorg. Med. Chem.,2005,13, (24),6771-6776.
[28]Rawal, R.K.; Tripathi, R.; Kulkarni, S.; Paranjape, R.; Katti, S.B.; Pannec ouque, C.; De Clercq, E.,2-(2,6-dihalo-phenyl)-3-heteroaryl-2-ylmethyl-1,3-thiazolidin-4-ones:anti-HIV agents. Chemical Biology & Drug Design,200 8,72, (2),147-154.
[29]Rawal, R.K.; Solomon, V.R.; Prabhakar, Y.S.; Katti, S.B.; De Clercq, E., Synthesis and QSAR studies on thiazolidinones as anti-HIV agents. Combi natorial Chemistry & High Throughput Screening,2005,8, (5),439-443.
[30]Rao, A.; Balzarini, J.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pannecouque, C; Zappala, M., Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Ⅱ Farmaco,2004,59, (1), 33-39.
[31]Rawal, R.K.; Prabhakar, Y.S.; Katti, S.B., Molecular surface features in m odeling the HIV-1 RT inhibitory activity of 2-(2,6-disubstituted phenyl)-3-(s ubstituted pyrimidin-2-yl)-thiazolidin-4-ones. Qsar & Combinatorial Science, 2007,26, (3),398-406.
[32]Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., D esign and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-o nes as anti-HIV agents. European Journal of Medicinal Chemistry,2008,4 3, (12),2800-2806.
[33]Rao, A.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monf orte, P.; Pannecouque, C.; Zappala, M., Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Ⅱ Farmaco,2002,57, (9), 747-751
[1]D'Cruz, O. J.; Uckun, F. M. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Enzyme I nhib. Med. Chem.,2006,21 (4),329-350.
[2]Menendez-Arias, L. Molecular basis of human immunodeficiency virus drug resistance:An update. Antiviral Res.,2010,85(1),210-231.
[3]Samuele, A.; Facchini, M.; Rotili, D.; Mai, A.; Artico, M.; Armand-Ugon, M.; Este, J. A.; Maga, G Substrate-induced stable enzyme-inhibitor comple x formation allows tight binding of novel 2-aminopyrimidin-4(3H)-ones to drug-resistant HIV-1 reverse transcriptase mutants. Chem. Med. Chem.,20 08,3(9),1412-1418.
[4]Mai, A.; Artico, M.; Ragno, R.; Sbardella, G.; Massa, S.; Musiu, C.; Mura, M.; Marturana, F.; Cadeddu, A.; Maga, G.; La Colla, P.5-Alkyl-2-alkyla mino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new seri es of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family. Bioorg. Med. Chem.,2005,13,2065-207 7.
[5]M. Botta, M. Artico, S. Massa, A. Gambacorta, M. Marongiu,A. Pani, P. L a Colla. Synthesis, antimicrobial and antiviral activities of isotrimethoprim and some related derivatives. Eur. J. Med. Chem.,1992,27,251-257.
[6]Artico, M.; Massa, S.; Mai, A.; Marongiu, M. E.; Piras, G.; Tramontano, E.; La Colla, P.3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): A New Class of Specific Inhibitors of Human Immunodeficiency Virus Ty pe 1. Antiviral Chem. Chemother.,1993,4,361-368.
[7]Yang S, Chen FE, De Clercq E. Dihydro-alkoxyl-benzyl-oxopyrimidine deri vatives (DABOs) as non-nucleoside reverse transcriptase inhibitors:an upda te review (2001-2011).Curr. Med. Chem.,2012,19(2):152-62.
[8]Erk N. Studies on veterinary manuscripts in Turkey and three samples fro m the 9th,12th and 14th centuries. Hist. Med. Vet.,2002,27(1-4):159-75.
[9]Yu M, Fan E, Wu J, Liu X. Recent advances in the DABOs family as pot ent HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Med. Che m.,2011,18(16):2376-85.
[10]Tramontano, E.; Marongiu, M. E.; De Montis, A.; Loi, A. G.;Artico, M.; Massa, S.; Mai, A.; La Colla, P. Characterization of the Anti-HIV-1 Activi ty of 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), New Non-Nucleoside Reverse Transcriptase Inhibitors. New Microbiol.,1994,17,269-279.
[11]Massa, S.; Mai, A.; Artico, M.; Sbardella, G.; Tramontano, E.;Loi, A. G.; Scano, P.; La Colla, P. Synthesis and Antiviral Activity of New 3,4-Dihyd ro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), Specific Inhibitors of Hu man Immunodeficiency Virus Type-1. Antivir. Chem. Chemother.,1995,6, 1-8.
[12]Mai, A.; Artico, M.; Sbardella, G.; Massa, S.; Loi, A. G.; Tramontano, E.; Scano, P.; La Colla, P. Synthesis and anti-HIV-1 activity of thio analogue s of dihydroalkoxybenzyl oxopyrimidines. J. Med. Chem.,1995,38,3258-3263.
[13]Sudbeck E A, Mao C, Vig R, Venkatachalam TK, Tuel-Ahlqren L, et al. Structure-Based Design of Novel Dihydro-alkoxybenzyloxopyrimidine Deri vatives as Potent Nonnucleoside Inhibitors of the Human Immunodeficienc y Virus Reverse Transcriptase. Antimicrob Agents Chemother,1998,42(12): 3225-3233.
[14]Vig R, Mao C, Venkatachalam T K, Tuel-Ahlqren L, Sudbeck EA, et al. 5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as pote nt non-nucleoside reverse transcriptase inhibitors of S-DABO series. Bioorg. Chem. Lett.,1998,8(12):1461-1466.
[15]Manetti F, Este JA, Clotet-Codina I, Armand-Ugon M, Maga G., et al. Par allel solution-phase and microwave-assisted synthesis of new S-DABO deri vatives endowed with subnanomolar anti-HIV-1 activity. J. Med. Chem.,20 05,48(25):8000-8008.
[16]Togninelli, A.; Carmi, C.; Petricci, E.; Mugnain,i C.; Massa, S.; Corelli, F.; Botta, M. Solution-phase parallel synthesis of S-DABO analogues. Tet rahedron Letters,2006,47,65-67.
[17]Wang, Y. P.; Chen. F. E.; De Clercq, E.; Balzarini, J.; Pannecouque, C. S ynthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-s ubstituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem.,2009,44,1016-1023.
[18]He, Y.; Chen, F.; Sun, G.; Wang, Y.; De Clercq, E.; Balzarini, J.; Pannec ouque, C.5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylm ethyl) pyrimidin- 4(3H)-ones as an unique HIV reverse transcriptase inhibit ors of S-DABO series. Bioorg. Med. Chem. Lett.,2004,14,3173-3176.
[19]He, Y.; Chen, F.; Yu, X.; Wang, Y.; De Clercq, E.; Balzarini, J.; Panneco uque, C. Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synt hesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl) thio]-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones. Bioorg. Chem.,2004,32, 536-548.
[20]Buckheit, R.W. Jr.; Watson, K.; Fliakas-Boltz, V.; Russell, J.; Loftus, T. L.; Osterling, M. C.; Turpin, J. A.; Pallansch, L. A.; White, E.L.; Lee, J. W.; Lee, S. H.; Oh, J. W.; Kwon, H. S.; Chung, S. G.; Cho, E.H.SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother,2001,45,393-400.
[21]Wang, Y. P.; Chen, F. E.; De Clercq, E.; Balzarini, J.; Pannecouque, C. S ynthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarb onylmethylthio) pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 rever se transcriptase inhibitors. Bioorg. Med. Chem.,2008,16,3887-3894.
[22]Hopkins, A. L.; Ren, J. S.; Milton, J.; Hazen, R. J.; Chan, J. H.; Stuart, D. I.; Stammers, D. K. Design of non-nucleoside inhibitors of HIV-1 rev erse transcriptase with improved drug resistance properties.1. J. Med. Che m.,2004,47,5912-5922.
[23]Nawrozkij, M. B.; Rotili, D.; Tarantino, D.; Botta, G.; Eremiychuk, A. S.; Musmuca, I.; Ragno, R.; Samuele, A.; Zanoli, S.; Armand-Ugon, M.; Clo tet-Codina, I.; Novakov, I. A.; Orlinson, B. S.; Maga, G.; Este, J. A.; Arti co, M.; Mai, A.; 5-Alkyl-6- benzyl- 2-(2-oxo- 2-phenylethylsulfanyl) pyri midin- 4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-ben zyl-oxopyrimidine family with peculiar structure-activity relationship profile. J. Med. Chem.,2008,51,4641-4652.
[24]Yu, M.; Liu, X.; Li, Z.; Liu, S.; Pannecouque, C.; De Clercq, E. Synthesi s and biological evaluation of novel 2-(substituted phenylaminocarbonylmet hylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTI s. Bioorg. Med. Chem.,2009,17,7749-7754.
[25]Yu M, Li Z, Liu S, Fan E, Pannecouque C, De Clercq E, Liu X. Synthe sis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbony lmethylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Chem.Med.Che m.,2011,6(5):826-33.
[26]Beroza P, Suto MJ. Designing chiral libraries for drug discovery. Drug. Di scov. Today,2000,5(8):364-372.
[27]Quaglia M, Mai A, Sbardella G, Artico M, Ragno R, et al. Chiral resoluti on and molecular modeling investigation of rac-2-cyclopentylthio-6-[1-(2,6-d ifluorophenyl)ethyl]-3,4-dihydro-5-methylpyrimid in-4(3H)-one (MC-1047), a potent anti-HIV-1 reverse transcriptase agent of the DABO class. Chirality, 2001,13(2):75-80.
[28]Cirilli R, Ferretti R, La Torre F, Borioni A, Fares V, et al. Chiral HPLC separation and absolute configuration of novel S-DABO derivatives. Chirali ty,2009,21(6):604-612.
[29]Radi M, Maga G, Alongi M, Angeli L, Samuele A, et al. Discovery of c hiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivati ves as potent HIV-1 reverse transcriptase inhibitors with high activity agai nst clinically relevant mutants. J. Med. Chem.,2009,52(3):840-851.
[30]Pedersen O S, Petersen L, Brandt M, Pedersen CN EB. Synthesis of 5-Al kyl-6-arylmethyl-2-(7-bromo-3,5-dioxaheptylthio)-pyrimidin-4(1 H)-ones and 7-Oxopyrimidino-1,5,3-oxathiazepines as New S-DABO Analogues with A nti-HIV Activity. Monatshefte. Fur. Chemie.,1999,130(12):1499-1512.
[31]Sbardella G, Mai A, Artico M, Chimenti P, Massa S, et al. Structure-activ ity relationship studies on new DABOS:effect of substitutions at pyrimidi ne C-5 and C-6 positions on anti-HIV-1 activity. Antivir. Chem. Chemothe r.,2001,12(1):37-50.
[32]Mai A, Artico M, Sbaredella G, Massa S, Novellino E, et al.5-Alkyl-2-(alkylthio)- 6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin- 4(3H)- ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. J. Med. Chem.,1999,42(4):619-627.
[33]Mai A, Sbaredella G, Artico M, Ragno R, Massa S, et al. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5- alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem.,2001,44(16):2544-2554.
[34]Mai A, Artico M, Sbardella G, Quartarone S, Massa S, Loi AG, De Mont is A, Scintu F, Putzolu M, La Colla P. Dihydro(alkylthio)(naphthylmethyl)o xopyrimidines:novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. J. Med. Chem.,1997,40(10):1447-54.
[35]Ji L, Chen FE, De Clercq E, Balzarini J, Pannecouque C. Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl or a-c yanoarylmethyl)-3,4- dihydropyrimidin-4(3H)-ones as Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. J.Med.Chem,2007,50(8):1778-17 86.
[36]Nawrozkij MB, Rotili D, Tarantino D, Botta G, Eremiychuk AS, et al.5- Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a seri es of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile. J. Med. Chem.,2008, 51(15):4641-4652.
[37]Qin H, Liu C, Guo Y, Wang R, Zhang J, Ma L, Zhang Z, Wang X, Cui Y, Liu J. Synthesis and biological evaluation of novel C5 halogen-functio nalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhib itors. Bioorg. Med. Chem.,2010,18(9):3231-7.
[1]Das, K.; Clark, A.D.; Lewi, P.J.; Heeres, J.; De Jonge, M.R.; Koymans, L. M.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J.; De Corte, B.; Kavash, R.W.; Ho, C.Y.; Ye, H.; Lichtenstein, M.A.; Andries, K.; Pau wels, R.; de Bethune, M.-P.; Boyer, P.L.; Clark, P.; Hughes, S.H.; Janssen, P.A.; Arnold, E. Roles of conformational and positional adaptability in str ucture-based design of TMC125-R165335 (etravirine) and related non-nucle oside reverse transcriptase inhibitors that are highly potent and effective ag ainst wild-type and drug-resistant HIV-1 variants. J. Med. Chem.,2004,47, 2550-2560.
[2]Lansdon, E.B.; Brendza, K.M.; Hung, M.; Wang, R.; Mukund, S.; Jin, D.; Birkus, G.; Kutty, N.; Liu, X.H. Crystal structures of HIV-1 reverse transcr iptase with etravirine (TMC125) and rilpivirine (TMC278):implications for drug design. J. Med. Chem.,2010,53,4295-4299.
[3]Das, K.; Bauman, J.D., Clark Jr., A.D., Frenkel, Y.V., Lewi, P.J., Shatkin, A.J., Hughes, S.H., Arnold, E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes:strategic flexibility explains potency again st resistance mutations. Proc. Natl. Acad. Sci. USA,2008,105,1466-71.
[4]Udier-Blagovic, M.; Tirado-Rives, J.; Jorgensen, W.L. Validation of a model for the complex of HIV-1 reverse transcriptase with non-nucleoside inhibi tor TMC125. J. Am. Chem. Soc.,2003,125,6016-6017.
[5]Zhan, P. Liu, X.Y.; Li, Z.Y.; Pannecouque, C.; De Clercq, E. Design strate gies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem.,20 09,16,3903-3917.
[6]Fattorusso, C.; Gemma, S.; Butini, S.; Huleatt, P.; Catalanotti, B.; Persico, M.; De Angelis, M.; Fiorini, I.; Nacci, V.; Ramunno, A.; Rodriquez, M.; Greco, G.; Novellino, E.; Bergamini, A.; Marini, S.; Coletta, M.; Maga, G.; Spadari, S.; Campiani, G. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region.design, synthesis, and bi ological evaluation of novel, potent, and broad spectrum NNRTIs with anti viral activity. J. Med. Chem.,2005,48,7153-7165.
[7]Butini, S.; Brindisi, M.; Cosconati, S.; Marinelli, L.; Borrelli, G.; Coccone, S.S.; Ramunno, A.; Campiani, G.; Novellino, E.; Zanoli, S.; Samuele, A.; Giorgi, G.; Bergamini, A.; Mattia, M.D.; Lalli, S.; Galletti, B.; Gemma, S.; Maga, G. Specific targeting of highly conserved residues in the HIV-1 re verse transcriptase primer grip region.2. stereoselective interaction to over come the effects of drug resistant mutations. J. Med. Chem.,2009,52,12 24-1228.
[8]Ren, J.; Nichols, C.; Bird, L.E.; Fujiwara, T.; Sugimoto, H.; Stuart, D.I.; St ammers, D.K. Binding of the second generation nonnucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydroge n bonding. J. Biol. Chem.,2000,275,14316-14320.
[9]Fang, C.; Bauman, J.D.; Das, K.; Remorino, A.; Arnold, E.; Hochstrasser, R.M. Two dimensional infrared spectra reveal relaxation of the non-nucleos ide inhibitor TMC278 complexed with HIV-1 reverse transcriptase. Proc. N atl. Acad. Sci. USA,2008,105,1472-1477.
[10]Hopkins, A.L.; Ren, J.; Milton, J.; Hazen, R.J.; Chan, J.H.; Stuart, D.I.; S tammers, D.K. Design of non-nucleoside inhibitors of HIV-1 reverse transc riptase with improved drug resistance properties 1. J. Med. Chem.,2004, 47,5912-5922.
[11]Hopkins, A.L.; Ren, J.; Esnouf, R.M.; Willcox, B.E.; Jones, E.Y.; Ross, C.; Miyasaka, T.; Walker, R.T.; Tanaka, H.; Stammers, D.K.; Stuart, D.I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT seri es reveal conformational changes relevant to the design of potent non-nucl eoside inhibitors. J. Med. Chem.,1996,39,1589-1600.
[12]Morphy, R.; Rankovic, Z. Designing multiple ligands-medicinal chemistry strategies and challenges. Curr. Pharm. Des.,2009,15,587-600.
[13]Zhan, P.; Liu, X.Y. Designed multiple ligands:an emerging anti-HIV drug discovery paradigm. Curr. Pharm. Des.,2009,15,1893-1917.
[14]K. D. Vyas, R. Nair, V. K. Jadhav, N. Bhatt, S. K.Deshmukh, P. P. Pansa re, R. K.Singh, A. M. Panandikar, Process for preparation of nitropyridine derivatives. WO2010089773.
[15]S. Bahceci, B. Chan, D. S. Chan, J. Chen, T. P. Forsyth, M. Franzini, V. Jammalamadaka, J. W. Jeong, L. R. Jeong, R. M. Kelley, M. H. Kim, J. W. Leahy, M. B. Mac, R. T. Noguchi, P. Rao, B. H. Ridgway, W. Xu, Y. Wang. CDK Modulators. WO2010003133.
[16]Tian X, Qin B, Wu Z, Wang X, Lu H, Morris-Natschke SL, Chen CH, Ji ang S, Lee KH, Xie L. Design, synthesis, and evaluation of diarylpyridine s and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase in hibitors. J Med Chem.,2010,53(23):8287-97.
[17]Jones CD, Andrews DM, Barker AJ, Blades K, Byth KF, Finlay MR, Ge h C, Green CP, Johannsen M, Walker M, Weir HM. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bi oorg. Med. Chem. Lett.,2008,18(24):6486-9.
[18]D. Andrews, M.R. Finlay, C. Green, C. Jones.4-(4-(Imidazol-4-yl) pyrimi din-2-ylamino) benzamides as CDK inhinitors. WO2006064251.
[19]van Rijt SH, Peacock AF, Johnstone RD, Parsons S, Sadler PJ. Organome tallic osmium(II) arene anticancer complexes containing picolinate derivativ es. Inorg. Chem.,2009,48:1753-1762.
[20]D. Varlet, E. Fourmaintraux, P. Depreux, D. Lesieur. Synthesis of 4-[4'-(N, N-Dimethylsulfamoyl)piperazin-1-yl]pyridine Derivatives as Sorbitol Dehydr ogenase Potential Inhibitors. Heterocycles.2000,53:797-804.
[21]K. Wachi, A. Terada. Studies on 1,3-Benzoxazines. I. Synthesis of Prima ry 2-Aminopyridines via the Reaction of Imidoyl Chlorides of 1,3-Benzox azines with Pyridine N-Oxides. Chem. Pharm. Bull.,1980,28:465-472.
[22]M. Wozniak, A. Baranski, B. Szpakiewicz. Regioselectivity of the aminati on of some 3-nitropyridines by liquid ammonia/potassium permanganate. Li ebigs Ann. Chem.,1991,875-878.
[23]N. T. Tzvetkov, C. E. Miiller. Facile synthesis of 5-amino-and 7-amino-6-azaoxindole derivatives. Tetrahedron Lett.,2012,53:5597-5601.
[24]Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq. Rapid and automated tetrazolium-based colori metric assay for the detection of anti-HIV compounds. E. J. Virol. Method s 1988,20,309-321.
[25]Pannecouque, C.; Daelemans, D.; De Clercq, E. Tetrazolium-based colorim etric assay for the detection of HIV replication inhibitors:revisited 20 yea rs later. Nat Protocols.,2008,3,427-434.
[26]Popovic, M.; Sarngadharan, M. G.; Read, E.; Gallo, R. C. Detection, isola tion, and continuous production of cytopathic retroviruses (HTLV-Ⅲ) from patients with AIDS and pre-AIDS. Science 1984,224,497-500.
[27]Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Grest, J.;Dauget,C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Roz enbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retro virus from a patient at risk for acquired immune deficiency syndrome (AIDS). Scienc e 1983,220,868-871.
[28]Miyoshi, I.; Taguchi, H.; Kobonishi, I.; Yoshimoto, S.; Ohtsuki, Y.; Shirais hi, Y.; Akagi, T. Type C virus-producing cell lines derived from adult T c ell leukemia. Gann. Monogr.1982,28,219-228.
[29]Eberle J, Seibl R. A new method for measuring reverse transcriptase acti-vity by ELISA. J. Virol. Methods.,1992,40(3):347-56.
[30]Reverse Transcriptase Assay, Colorimetric Kit, Roche Diagnostics GmbH, Roche. Applied Science, Sandhofer Strasse 116, D-68305 Mannheim, Germ a.
[31]Suzuki K, Craddock BP, Okamoto N, Kano T, Steigbigel RT. Poly A-link ed colorimetric microtiter plate assay for HIV reverse transcriptase. J. Viro 1. Methods.,1993,44(2-3):189-98.
[1]Jan Balzarini, W G Brouwer, D C Dao, E M Osika, Erik De Clercq. Ident ification of Novel Thiocarboxanilide Derivatives That Suppress a Variety of Drug-Resistant Mutant Human Immunodeficiency Virus Type 1 Strains at a Potency Similar to That for Wild-Type Virus. Antimicrob. Agent. Chemo ther.,1996,1454-1466
[2]Balzarini, J., Naesens, L., Verbeken, E., Laga, M., Van Damme, L., Parniak, M., Van Mellaert, L., Anne, J., and De Clercq, E., Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS,1998,12,1129-38
[3]Barnard, J., Borkow, G, and Parniak, M. A., The thiocarboxanilide nonnucl eoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. B iochemistry,1997,36,7786-7792.
[4]Selhorst P, Vazquez AC, Terrazas-Aranda K, Michiels J, Vereecken K, Hey ndrickx L, Weber J, Quiiiones-Mateu ME, Arien KK, Vanham G. Human i mmunodeficiency virus type 1 resistance or cross-resistance to nonnucleosi de reverse transcriptase inhibitors currently under development as microbici des. Antimicrob. Agents. Chemother.,2011,55(4):1403-13.
[5]Bader, J. P., McMahon, J. B., Schultz, R. J., Narayanan, V. L., Pierce, J. B., Harrison, W. A., Weislow, O. S., Midelfort, C. F., Stinson, S. F., and Boyd, M. R., Oxathiin carboxanilide, a potent inhibitor of human immuno deficiency virus reproduction. Proc. Natl. Acad. Sci. U S A,1991,88 (1 5),6740-6744
[6]Balzarini, J., Pelemans, H., Aquaro, S., Perno, C., Witvrouw, M., D, D. S., Clercq, E. D., and Karlsson, A., Highly favorable antiviral activity and re sistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication., Mol. Pharmacol.,1996,50 (2),394-401
[7]Hossain, M. M. and Parniak, M. A., In Vitro Microbicidal Activity of the Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) UC781 against NN RTI-Resistant Human Immunodeficiency Virus Type 1. J. Virol.,2006,80 (9),4440-4446.
[8]Borkow, G, Arion, D., Wainberg, M. A., and Parniak, M. A. The thiocarb oxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azi do-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob. Agents. Chemother.,1999,43 (2),259-263.
[9]Buckheit, R. W., Jr., Snow, M. J., Fliakas-Boltz, V, Kinjerski, T. L., Russe 11, J. D., Pallansch, L. A., Brouwer, W. G, and Yang, S. S., Highly poten t oxathiin carboxanilide derivatives with efficacy against nonnucleoside rev erse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents. Chemother.,1997,41(4),831-837
[10]Borkow, G, Barnard, J., Nguyen, T. M., Belmonte, A., Wainberg, M. A., and Parniak, M. A. Chemical Barriers to Human Immunodeficiency Virus Type 1 (HIV-1) Infection:Retrovirucidal Activity of UC781,a Thiocarboxan ilide Nonnucleoside Inhibitor of HIV-1 Reverse Transcriptase. J. Virol.,19 97,71 (4),3023-3030.
[11]Zussman, A., Lara, L., Lara, H. H., Bentwich, Z., and Borkow, G. Blocki ng of cell-free and cell-associated HIV-1 transmission through human cervi x organ culture with UC781. AIDS.2003,17 (5),653-661.
[12]De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res.,1998,38(3):15 3-79.
[13]Robert M. Esnouf, Stuart, D.I., De Clercq, E., Schwartz, E., Balzarini, J., Models which explain the inhibition of reverse transcriptase by HIV-1-spe cific (thio)carboxanilide derivatives. Biochem. Biophys. Res. Commun.199 7,234,458-464.
[14]Rao GS, Bhatnagar S.In silico structure-based design of a potent, mutation resilient, small peptide inhibitor of HIV-1 reverse transcriptase.J. Biomol. Struct. Dyn.2003,21(2):171-8.
[15]Pelemans H, Esnouf R, De Clercq E, Balzarini J. Mutational analysis of t rp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational desig n of new non-nucleoside RT inhibitors. Mol. Pharmacol.,2000,57(5):954-60.
[16]Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Dar by G, Jones Y, Stuart D and Stammers D, High resolution structures of H Ⅳ-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol.,1995,2:293-302.
[17]Grasso, S.; Chimirri, A.; Monforte, P.; Fenech, G.; Zappala, M.; Monforte, A. M. Compounds with potential antitumor activity. VI--2-Alkyl-3-[2-(1,3, 4-thiadiazolyl)]-4-thiazolidinones. Ⅱ Farmaco.1988,43,851-6
[18]Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappala M.2-(2,6-Dihalophenyl)-3-(pyrimidin -2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase i nhibitors. Antiviral. Res.,2004,63(2):79-84.
[19]Ruiz-Caro J, Basavapathruni A, Kim JT, Bailey CM, Wang L, Anderson KS, Hamilton AD, Jorgensen WL. Optimization of diarylamines as non-nu cleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 2006,16(3):668-71.
[20]Thakur VV, Kim JT, Hamilton AD, Bailey CM, Domaoal RA, Wang L, Anderson KS, Jorgensen WL. Optimization of pyrimidinyl-and triazinyl-a mines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett.,2006,16(21):5664-7.
[1]Samuele A, Facchini M, Rotili D, Mai A, Artico M, Armand-Ugon M, Est e JA, Maga G. Substrate-induced stable enzyme-inhibitor complex formatio n allows tight binding of novel 2-aminopyrimidin-4(3H)-ones to drug-resist ant HIV-1 reverse transcriptase mutants. Chem. Med. Chem.,2008,3(9):14 12-8.
[2]de Brito MA, Rodrigues CR, Cirino JJ, de Alencastro RB, Castro HC, Alb uquerque MG.3D-QSAR CoMFA of a series of DABO derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors. J. Chem. Inf. Model.,20 08,48(8):1706-15.
[3]Mai A, Artico M, Rotili D, Tarantino D, Clotet-Codina I, Armand-Ugon M, Ragno R, Simeoni S, Sbardella G, Nawrozkij MB, Samuele A, Maga G, Este JA. Synthesis and biological properties of novel 2-aminopyrimidin-4(3 H)-ones highly potent against HIV-1 mutant strains. J. Med. Chem.,2007, 50(22):5412-24.
[4]Manetti F, Este JA, Clotet-Codina I, Armand-Uqon M, Maqa G, et al. Para-llel solution-phase and microwave-assisted synthesis of new S-DABO der ivatives endowed with subnanomolar anti-HIV-1 activity. J. Med. Chem.,2 005,48(25):8000-8008
[5]Mai A, Artico M, Ragno R, Sbardella G, Massa S, et al.5-Alkyl-2-alkyla mino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new se ries of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitor s belonging to the DABO family. Bioorg. Med. Chem.,2005,13(6):2065-2077.
[6]Aroyan A A,Kramer M S. Pyrimidine derivatives. Substituted 6-(4'-alkoxy benzyl)pyrimidines. Arm. Khim. Zh.,1971,24(2):161-166.
[7]Riegel B, Lilienfeld W M. The Synthesis of β-Keto Esters by the Decomp-osition of Acylated Malonic Esters. J. Am. Chem. Soc.,1945,67:1273-12 75.
[8]Monostory J. New derivatives on carbon atom 6 of thiouracil with antithyr-oidal effects. An. Asoc. Quim. Argent,1952,40:99-108.
[9]Clay R J, Collom T A, Karrick G L, Wemple K J. A safe, economical me-thod for the preparation of β-oxo ester. Synthesis,1993,290-292.
[10]Hannick S M, Kishi Y. An improved procedure for the Blaise reaction:a short, practical route to the key intermediates ofthe saxitoxin synthesis. J. Org. Chem.,1983,48:3833-3835.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |